A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease

  1. Qingyuan Zhao  Is a corresponding author
  2. Jingshu Wang
  3. Zhen Miao
  4. Nancy R Zhang
  5. Sean Hennessy
  6. Dylan S Small
  7. Daniel J Rader
  1. Statistical Laboratory, University of Cambridge, United Kingdom
  2. Department of Statistics, University of Chicago, United States
  3. Perelman School of Medicine, University of Pennsylvania, United States
  4. Department of Statistics, University of Pennsylvania, United States
  5. Department of Medicine, University of Pennsylvania, United States

Abstract

Recent genetic data can offer important insights into the roles of lipoprotein subfractions and particle sizes in preventing coronary artery disease (CAD), as previous observational studies have often reported conflicting results. We used the LD score regression to estimate the genetic correlation of 77 subfraction traits with traditional lipid profile and identified 27 traits that may represent distinct genetic mechanisms. We then used Mendelian randomization (MR) to estimate the causal effect of these traits on the risk of CAD. In univariable MR, the concentration and content of medium high-density lipoprotein (HDL) particles showed a protective effect against CAD. The effect was not attenuated in multivariable analyses. Multivariable MR analyses also found that small HDL particles and smaller mean HDL particle diameter may have a protective effect. We identified four genetic markers for HDL particle size and CAD. Further investigations are needed to fully understand the role of HDL particle size.

Introduction

Lipoprotein subfractions have been increasingly studied in epidemiological research and used in clinical practice to predict the risk of cardiovascular diseases (CVD) (Rankin et al., 2014; Mora et al., 2009; China Kadoorie Biobank Collaborative Group et al., 2018). Several studies have identified potentially novel subfraction predictors for CVD (Mora et al., 2009; Hoogeveen et al., 2014; Williams et al., 2014; Ditah et al., 2016; Lawler et al., 2017; Fischer et al., 2014) and demonstrated that the addition of subfraction measurements can significantly improve the risk prediction for CVD (Würtz et al., 2012; van Schalkwijk et al., 2014; McGarrah et al., 2016; Rankin et al., 2014). However, these observational studies often provide conflicting evidence on the precise roles of the lipoprotein subfractions. For example, while some studies suggested that small, dense low-density lipoprotein (LDL) particles may be more atherogenic (Lamarche et al., 1997; Hoogeveen et al., 2014), others found that larger LDL size is associated with higher CVD risk (Campos et al., 2001; Mora, 2009). Some recent observational studies found that the inverse association of CVD outcomes with smaller high-density lipoprotein (HDL) particles is stronger than the association with larger HDL particles (Ditah et al., 2016; Kim et al., 2016; McGarrah et al., 2016; Silbernagel et al., 2017), but other studies reached the opposite conclusion in different cohorts (Li et al., 2016; Arsenault et al., 2009). Currently, the utility of lipoprotein subfractions or particle sizes in routine clinical practice remains controversial (Superko, 2009; Mora, 2009; Davidson et al., 2011; Bays et al., 2016), as there is still a great uncertainty about their causal roles in CVD, largely due to a lack of intervention data (Bays et al., 2016).

Mendelian randomization (MR) is an useful causal inference method that avoids many common pitfalls of observational cohort studies (Smith and Ebrahim, 2003). By using genetic variation as instrumental variables, MR asks if the genetic predisposition to a higher level of the exposure (in this case, lipoprotein subfractions) is associated with higher occurrences of the disease outcome (Didelez and Sheehan, 2007). A positive association suggests a causally protective effect of the exposure if the genetic variants satisfy the instrumental variable assumptions (Didelez and Sheehan, 2007; Davey Smith and Hemani, 2014). Since MR can provide unbiased causal estimate even when there are unmeasured confounders, it is generally considered more credible than other non-randomized designs and is quickly gaining popularity in epidemiological research (Gidding et al., 2012; Davies et al., 2018). MR has been used to estimate the effect of several metabolites on CVD, but most prior studies are limited to just one or a few risk exposures at a time (Emdin et al., 2016; Ference et al., 2017).

In this study, we will use recent genetic data to investigate the roles of lipid and lipoprotein traits in the occurrence of coronary artery disease (CAD) and myocardial infarction (MI). In particular, we are interested in discovering lipoprotein subfractions that may be causal risk factors for CAD and MI in addition to the traditional lipid profile (LDL cholesterol, HDL cholesterol, and triglycerides levels). To this end, we will first estimate the genetic correlation of the lipoprotein subfractions and particle sizes with the tradition risk factors and remove the traits that have a high genetic correlation. We will then use MR to estimate the causal effects of the selected lipoprotein subfractions and particle sizes on CAD and MI. Finally, we will explore potential genetic markers for the identified lipoprotein and subfraction traits.

Materials and methods

GWAS summary datasets and lipoprotein particle measurements

Request a detailed protocol

Table 1 describes all GWAS summary datasets used in this study, including two GWAS of the traditional lipid risk factors (Willer et al., 2013; Hoffmann et al., 2018), two recent GWAS of the human lipidome (Kettunen et al., 2016; Davis et al., 2017), and three GWAS of CAD or MI (Nikpay et al., 2015; Nelson et al., 2017; Abbott et al., 2018). In the two GWAS of the lipidome (Kettunen et al., 2016; Davis et al., 2017), high-throughput nuclear magnetic resonance (NMR) spectroscopy was used to measure the circulating lipid and lipoprotein traits (Soininen et al., 2009). We investigated the 82 lipid and lipoprotein traits measured in these studies that are related to very-low-density lipoprotein (VLDL), LDL, intermediate-density lipoprotein (IDL), and HDL subfractions and particle sizes. All the subfraction traits are named with three components that are separated by hyphens: the first component indicates the size (XS, S, M, L, XL, XXL); the second component indicates the fraction according to the lipoprotein density (VLDL, LDL, IDL, HDL); the third component indicates the measurement (C for total cholesterol, CE for cholesterol esters, FC for free cholesterol, L for total lipids, P for particle concentration, PL for phospholipids, TG for triglycerides). For example, M-HDL-P refers to the concentration of medium HDL particles.

Table 1
Information about the GWAS summary datasets used in this article.

The columns are the phenotypes reported by the GWAS studies, the consortium or name of the first author of the publication, PubMed ID, population, sample size, other GWAS datasets with other lapping sample, and URLs we used to download the datasets.

PhenotypeDataset namePubMed IDPopulationSample sizeSample overlap with other datasetsURL to summary dataset
Traditional lipid traitsGERA29507422 Hoffmann et al., 2018Multi-ethnic94,674ftp://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/
GLGC24097068 Willer et al., 2013European188,578Kettunen, CARDIoGRAMplusC4Dhttp://csg.sph.umich.edu/abecasis/public/lipids2013/
Lipoprotein subfraction traitsDavis29084231 Davis et al., 2017Finnish8372http://csg.sph.umich.edu/boehnke/public/metsim-2017-lipoproteins/
Kettunen27005778 Kettunen et al., 2016European24,925GLGC, CARDIoGRAMplusC4Dhttp://www.computationalmedicine.fi/data#NMR_GWAS
Heart disease traitsCARDIoGRAMplusC4D (CAD)26343387 Nikpay et al., 2015Mostly European185,000GLGC, Kettunenhttp://www.cardiogramplusc4d.org/data-downloads/
CARDIoGRAMplusC4D + UK Biobank (CAD)28714975 Nelson et al., 2017Mostly European
UK Biobank (MI)Interim round two release Abbott et al., 2018European360,420http://www.nealelab.is/uk-biobank/

Aside from the concentration and content of lipoprotein subfractions, the two lipidome GWAS also measured the traditional lipid traits (TG, LDL-C, HDL-C), the average diameter of the fractions (VLDL-D, LDL-D, HDL-D) and the concentration of apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB). A full list of the lipoprotein measurements investigated in this article can be found in Appendix 1.

Genetic correlation and phenotypic screening

Request a detailed protocol

Genetic correlation is a measure of association between the genetic determinants of two phenotypes. It is conceptually different from epidemiological correlation that can be directly estimated from cross-sectional data. In this study, we applied the LD-score regression (Bulik-Sullivan et al., 2015) to the lipidome GWAS (Kettunen et al., 2016; Davis et al., 2017) to estimate the genetic correlations between the lipoprotein subfractions, particle sizes, and traditional risk factors. We then removed lipoprotein subfractions and particle sizes that are strongly correlated with the traditional risk factors, defined as an estimated genetic correlation > 0.8 with TG, LDL-C, HDL-C, ApoB, or ApoA1 in the GWAS published by Davis et al., 2017. Because these traits are largely co-determined with the traditional risk factors, they do not represent independent biological mechanisms and may lead to multicollinearity issues in multivariate MR analyses. Finally, we obtained an independent estimate of the genetic correlations between the selected traits by applying the LD score regression to the GWAS published by Kettunen et al., 2016. We used Bonferroni's procedure to correct for multiple testing (familywise error rate at 0.05).

Three-sample Mendelian randomization design

Request a detailed protocol

For MR, we employed a three-sample design (Zhao et al., 2019b) in which one GWAS was used to select independent genetic instruments that are associated with one or several lipoprotein measures. The other two GWAS were then used to obtain summary associations of the selected SNPs with the exposure and the outcome, as in a typical two-sample MR design (Pierce and Burgess, 2013; Hemani et al., 2016). More specifically, the selection GWAS was used to create a set of SNPs that are in linkage equilibrium with each other in a reference panel (distance >10 megabase pairs, r2<0.001). This was done by ordering the SNPs by the p-values of their association with the trait(s) under investigation and then selecting them greedily using the linkage-disequilibrium (LD) clumping function in the PLINK software package (Purcell et al., 2007). To avoid winner's curse, we require the other two GWAS to have no overlapping sample with the selection GWAS.

As the GWAS published by Davis et al., 2017 has a smaller sample size, we used it to select the genetic instruments so the larger dataset can be used for statistical estimation. In univariable MR, associations of the selected SNPs with the exposure trait (a lipoprotein subfraction or a particle size trait) were obtained from the GWAS published by Kettunen et al., 2016 and the associations with MI were obtained using summary data from an interim release of UK BioBank (Abbott et al., 2018). To maximize the statistical power, we used the so-called ‘genome-wide MR’ design. Independent SNPs are selected by using LD clumping, but we do not truncate the list of SNPs by their p-values. More details about this design can be found in a previous methodological article (Zhao et al., 2019b).

To control for potential pleiotropic effects via the traditional risk factors, we performed two multivariable MR analyses for each lipoprotein subfraction or particle size under investigation. The first multivariable MR analysis considers four exposures: TG, LDL-C, HDL-C, and the lipoprotein measurement under investigation. The second multivariable MR analysis replaces LDL-C and HDL-C with ApoB and ApoA1, in accordance with some recent studies (Richardson et al., 2020). SNPs were ranked by their minimum p-values with the four exposures and are selected as instruments only if they were associated with at least one of the four exposures (p-value 10-4). Both multivariable MR analyses used the Davis (Davis et al., 2017) and GERA (Hoffmann et al., 2018) datasets for instrument selection, the Kettunen (Kettunen et al., 2016) and GLGC (Willer et al., 2013) datasets for the associations of the instruments with the exposures, and the CARDIoGRAMplusC4D + UK Biobank (Nelson et al., 2017) dataset for the associations with CAD.

Statistical estimation

Request a detailed protocol

For univariable MR, we used the robust adjusted profile score (RAPS) because it is more efficient and robust than many conventional methods (Zhao et al., 2020; Zhao et al., 2019b). RAPS can consistently estimate the causal effect even when some of the genetic variants violate instrumental variables assumptions. For multivariable MR, we used an extension to RAPS called GRAPPLE to obtain the causal effect estimates of multiple exposures (Wang et al., 2020). GRAPPLE also allows the exposure GWAS to have overlapping sample with the outcome GWAS, while the original RAPS does not. We assessed the strength of the instruments using the modified Cochran's Q statistic (Sanderson et al., 2019). Because many lipoprotein subfraction traits were analyzed simultaneously, we used the Benjamini-Hochberg procedure to correct for multiple testing (Benjamini and Hochberg, 1995) and the false discovery rate was set to be 0.05. More detail about the statistical methods can be found in Appendix 3.

Table 2
Results of some multivariable Mendelian randomization analyses.

Each row in the table corresponds to a multivariable MR analysis with traditional lipid profile and the specified lipoprotein subfraction or particle size trait. Reported numbers are the point estimates and 95% confidence intervals of the exposure effect.

TraitEffect of TGEffect of LDL-CEffect of HDL-CEffect of subfraction/particle size
None0.19 [0.09,0.29]0.38 [0.33,0.44]−0.053 [-0.13,0.03]
M-HDL-P0.37 [0.22,0.52]0.39 [0.32,0.45]0.30 [0.08,0.52]−0.69 [-1.09,–0.3]
S-HDL-P0.23 [0.12,0.33]0.45 [0.38,0.52]−0.11 [-0.2,–0.02]−0.33 [-0.52,–0.15]
HDL-D0.11 [0.00,0.22]0.42 [0.36,0.49]−0.44 [-0.69,–0.2]0.33 [0.11,0.56]
Effect of TGEffect of ApoBEffect of ApoA1Effect of Subfraction/Particle size
None0.05 [-0.05,0.14]0.49 [0.38,0.60]−0.095 [-0.21,0.02]
M-HDL-P−0.00 [-0.18,0.17]0.50 [0.31,0.69]0.13 [-0.06,0.32]−0.47 [-0.80,–0.15]
S-HDL-P0.07 [-0.03,0.17]0.53 [0.41,0.65]−0.13 [-0.25,–0.02]−0.24 [-0.40,–0.08]
HDL-D0.06 [-0.04,0.15]0.61 [0.47,0.76]−0.46 [-0.73,–0.19]0.30 [0.08,0.52]

Genetic markers for lipoprotein subfractions and CAD

Request a detailed protocol

To obtain genetic markers, we selected SNPs that are associated with the lipoprotein measurements identified in the MR (p-value 5×10-8) and CAD (p-value 0.05) but are not associated with LDL-C or ApoB (p-value 10-3). To maximize the power of this exploratory analysis, we meta-analyzed the results of the two lipidome GWAS (Kettunen et al., 2016; Davis et al., 2017) by inverse-variance weighting. For the associations with LDL-C and CAD, we used the GWAS summary data reported by the GLGC (Willer et al., 2013) and CARDIoGRAMplusC4D (Nelson et al., 2017) consortia. We used LD clumping to obtain independent markers (Purcell et al., 2007) and then validate the markers using tissue-specific gene expression data from the GTEx project.

Sensitivity analysis and replicability

Request a detailed protocol

Because we had multiple GWAS summary datasets for the lipoprotein subfractions and CAD/MI (Table 1), we swapped the roles of the GWAS datasets in the three-sample MR design whenever permitted by the statistical methods to obtain multiple statistical estimates. These estimates are not completely independent of the primary results, but they can nonetheless be used to assess replicability. As a sensitivity analysis, We further analyzed univariable MR using inverse-variance weighting (IVW) (Burgess et al., 2013) and weighted median (Bowden et al., 2016) and compared with the primary results obtained by RAPS. We also assessed the assumptions made by RAPS using some diagnostic plots suggested in previous methodological articles (Zhao et al., 2019b).

Results

Genetic correlations and phenotypic screening

We obtained the genetic correlations of the lipoprotein subfractions and particle sizes with the traditional lipid risk factors: TG, LDL-C, HDL-C, ApoB, and ApoA1 (Table 1). We found that almost all VLDL subfractions traits (besides those related to very small VLDL subfraction) and the mean VLDL particle diameter have an estimated genetic correlation with TG very close to 1. Most traits related to the large and very large HDL subfractions also have a high genetic correlation with HDL-C and ApoA1.

After removing traits that are strongly correlated with the traditional risk factors, we obtained 27 traits that may involve independent genetic mechanisms. Figure 1 shows the genetic correlation matrix for these traits and the traditional lipid factors. The selected traits can be divided into two groups based on whether they are related to VLDL/LDL/IDL particles or HDL particles. Within each group, most traits were strongly correlated with the others. In the first group, most traits had a positive genetic correlation with LDL-C and ApoB, while in the second group, most traits had a positive genetic correlation with HDL-C and ApoA1. Exceptions include LDL-D, which had a negative but statistically non-significant genetic correlation with LDL-C and ApoB, and S-HDL-P and S-HDL-L, which showed no or weak genetic correlation with HDL-C and ApoA1.

Genetic correlation matrix of the 27 lipoprotein subfraction traits selected in phenotypic screening and five traditional lipid traits.

White asterisk indicates the correlation is statistically significant after Bonferroni correction for multiple comparisons at level 0.05.

Mendelian randomization

Figure 2 shows the estimated causal effect of the selected lipoprotein measurements on MI or CAD that are statistically significant (false discovery rate = 0.05). The unfiltered results can be found in Appendix 3, which also contains results of the sensitivity and replicability analyses.

Results of the Mendelian randomization analyses (false discover rate = 0.05): Estimated odds ratio [95% confidence interval] per standard deviation increase of the selected lipoprotein measurements on MI or CAD.

The concentration and lipid content of VLDL, LDL, and IDL subfractions showed harmful and nearly uniform effects on MI in univariable MR. However, after adjusting for the traditional lipid risk factors, the effects of these ApoB-related subfractions become close to zero (besides IDL-FC in one multivariable analysis). The mean diameter of LDL particles (LDL-D) showed a harmful effect on MI in univariable MR, though the effect was smaller than those of the LDL subfractions in univariable MR. The estimated effect of LDL-D was attenuated in the multivariable MR analyses.

The concentration and content of medium HDL particles showed protective effects in univariable and multivariable MR analyses. In particular, adjusting for the traditional lipid risk factors did not attenuate the effect of traits related to medium HDL. The concentration of and total lipid in small HDL particles showed protective effects in multivariable MR analyses, though the effect sizes were smaller than those of the medium HDL traits. The mean diameter of HDL particles (HDL-D) had almost no effect on MI in the univariable MR analysis, but after adjusting for the traditional lipid risk factors, it showed a harmful effect.

Table 2 reports the estimated effects of M-HDL-P, S-HDL-P, HDL-D, and traditional lipid traits (TG, LDL-C, HDL-C, ApoB, ApoA1) in the multivariable MR analyses. To better understand the role of HDL subfractions and particle sizes, we also included in the table the results of the multivariate MR analyses for the traditional lipid risk factors only. Those baseline analyses suggested that HDL-C/ApoA1 had a weak, non-significant protective effect on CAD, which is consistent with prior studies (Holmes et al., 2015; Wang et al., 2020). Adding S-HDL-P to the MR analysis did not substantially alter the estimated effects of the traditional lipid traits. However, when M-HDL-P or HDL-D was included in the model, the estimated effects of M-HDL-P and HDL-D changed substantially. In particular, when M-HDL-P was included in the multivariable MR analyses, HDL-C/ApoA1 showed a harmful effect on CAD. When HDL-D was included, HDL-C/ApoA1 showed a protective effect.

Genetic markers associated with HDL subfractions and CAD

We identified four genetic variants that are associated with S-HDL-P, M-HDL-P, or HDL-D, not associated with LDL-C or ApoB, and associated with CAD: rs838880 (SCARB1), rs737337 (DOCK6), rs2943641 (IRS1), and rs6065904 (PLTP) (Figure 3). These SNP-cis gene pairs are also supported by examining expression quantitative trait loci (eQTL) in the tissue-specific GTEx data (Appendix 4). The first three variants were not associated with S-HDL-P. However, they had uniformly positive associations with M-HDL-P, L-HDL-P, XL-HDL-P, HDL-D, ApoA1, and HDL-C, and a negative association with CAD. The last variant rs6065904 had positive associations with S-HDL-P and M-HDL-P, negative associations with L-HDL-P, XL-HDL-P, HDL-D, negative but smaller associations with ApoA1 and HDL-C, and a negative association with CAD.

Genetic markers for HDL size (with risk alleles) and their associations with various lipid traits.

Sensitivity and replicability analysis

We also investigated the effects of lipoprotein subfractions and particle sizes on MI/CAD using multiple GWAS datasets, MR designs and statistical methods. The results are provided in Appendix 3 and are generally in agreement with the primary results reported above. The diagnostic plots for S-HDL-P and M-HDL-P did not suggest evidence of violations of the instrument strength independent of direct effect (InSIDE) assumption (Bowden et al., 2015) made by RAPS and GRAPPLE (Appendix 4).

Discussion

By using recent genetic data and MR, this study examines whether some lipoprotein subfractions and particle sizes, beyond the traditional lipid risk factors, may play a role in coronary artery disease. We find that VLDL subfractions have extremely high genetic correlations with blood triglyceride level and thus offer little extra value. We find some weak evidence that larger LDL particle size may have a small harmful effect on myocardial infarction and coronary artery disease.

Our main finding is that the size of HDL particles may play an important and previously undiscovered role. Although the concentration and lipid content of small and medium HDL particles appear to be positively correlated with HDL cholesterol and ApoA1, their genetic correlations are much smaller than 1, indicating possible independent biological pathway(s). Moreover, the MR analyses suggested that the small and medium HDL particles may have protective effects on CAD. We also find that larger HDL mean particle diameter may have a harmful effect on CAD. Finally, we identified four potential genetic markers for HDL particle size that are independent of LDL cholesterol and ApoB.

There has been a heated debate on the role of HDL particles in CAD in recent years following the failure of several trials for CETP inhibitors (Barter et al., 2007; Schwartz et al., 2012; Lincoff et al., 2017) and recombinant ApoA1 (Nicholls et al., 2018) targeting HDL cholesterol. Observational epidemiology studies have long demonstrated strong inverse association between HDL cholesterol and the risk of CAD or MI (Miller and Miller, 1975; Lewington et al., 2007; Di Angelantonio et al., 2009), but conflicting evidence has been found in MR studies. In an influential study, Voight and collaborators found that the genetic variants associated with HDL cholesterol had varied associations with CAD and that almost all variants suggesting a protective effect of HDL cholesterol were also associated with LDL cholesterol or triglycerides (Voight et al., 2012). Other MR studies also found that the effect of HDL cholesterol on CAD is heterogeneous (Zhao et al., 2019b) or attenuated after adjusting for LDL cholesterol and triglycerides (Holmes et al., 2017; White et al., 2016).

Notice that the harmful effect of larger HDL particle diameter found in this study relies on including HDL-C or ApoA1 in the multivariable MR analysis. Thus, the role of HDL particles in preventing CAD may be more complicated than, for example, that of LDL cholesterol or ApoB. It is possible that HDL cholesterol, HDL subfractions, and HDL particle size are all phenotypic markers for some underlying causal mechanism. A related theory is the HDL function hypothesis (Rader and Hovingh, 2014). Cholesterol efflux capacity, a measure of HDL function, has been documented as superior to HDL-C in predicting CVD risk (Rohatgi et al., 2014; Saleheen et al., 2015). Recent epidemiologic studies found that HDL particle size is positively associated with cholesterol efflux capacity in post-menopausal women (El Khoudary et al., 2016) and in an asymptomatic older cohort (Mutharasan et al., 2017). However, mechanistic efflux studies showed that small HDL particles actually mediate more cholesterol efflux (Favari et al., 2009; Du et al., 2015). A likely explanation of this seeming contradiction is that a high concentration of small HDL particles in the serum may mark a block in maturation of small HDL particles (Mutharasan et al., 2017). This can also partly explain our finding that small HDL traits have a smaller effect than medium HDL traits, as increased medium HDL might indicate successful maturation of small HDL particles.

Among the reported genetic markers, SCARB1 and PLTP have established relations to HDL metabolism and CAD. SCARB1 encodes a plasma membrane receptor for HDL and is involved in hepatic uptake of cholesterol from peripheral tissues. Recently, a rare mutation (P376L) of SCARB1 was reported to raise HDL-C level and increase CAD risk (Zanoni et al., 2016; Samadi et al., 2019). This is opposite direction to the conventional belief that HDL-C is protective and could be explained by HDL dysfunction. PLTP encodes the phospholipid transfer protein and mediates the transfer of phospholipid and cholesterol from LDL and VLDL to HDL. As a result, PLTP plays a complex but pivotal role in HDL particle size and composition. Several studies have suggested that high PLTP activity is a risk factor for CAD (Schlitt et al., 2003; Schlitt et al., 2009; Zhao et al., 2019a).

Our study should be viewed in the context of its limitations, in particular, the inherent limitations of the summary-data MR design. Any causal inference from non-experimental data makes unverifiable assumptions, so does our study. Conventional MR studies assume that the genetic variants are valid instrumental variables. The statistical methods used by us make less stringent assumptions about the instrumental variables, but those assumptions could still be violated even though our model diagnosis does not suggest evidence against the InSIDE assumption. Our study did not adjust for other risk factors for CAD such as body mass index, blood pressure, and smoking. All the GWAS datasets used in this study are from the European population, so the same conclusions might not generalize to other populations. Furthermore, our study used GWAS datasets from heterogeneous subpopulations, which may also introduce bias (Zhao et al., 2019c). We also did not use more than one subfraction traits as exposures in multivariable MR because of their high genetic correlations. Alternative statistical methods could be used to select the best causal risk factor from high-throughput experiments (Zuber et al., 2019). Finally, as pointed out by revieweres, triglycerides has a greater intra-individual biological variability than HDL particle size. It is likely that triglycerides and HDL size represent a gene/environment interaction with a very large environmental component. Further investigations are needed to fully understand this mechanism.

Recently, a NMR spectroscopy method has been developed to estimate HDL cholesterol efflux capacity from serum (Kuusisto et al., 2019). That method can form the basis of a genetic analysis of HDL cholesterol efflux capacity and may complement the results here. We believe more laboratorial and epidemiological research is needed to clarify the roles of HDL subfractions and particle size in cardiovascular diseases.

Appendix 1

Lipid and lipoprotein traits

Two published GWAS of the human lipidome [Kettunen2016, Davis2017] measured lipoprotein subfractions and particle sizes using NMR spectroscopy. We investigated the 82 lipid and lipoprotein traits measured in these studies that are related to very-low-density lipoprotein (VLDL), LDL, and HDL subfractions and particle sizes. All the subfraction traits are named using three components separated by hyphen: the first indicates the size (XS, S, M, L, XL, XXL); the second indicates the category according to the lipoprotein density (VLDL, LDL, IDL, HDL); the third indicates the measurement (C for total cholesterol, CE for cholesterol esters, FC for free cholesterol, L for total lipids, P for particle concentration, PL for phospholipids, TG for triglycerides). A full list of lipid and lipoprotein traits used in our study can be found in Appendix 1—table 1 below.

Appendix 1—table 1
All 82 traits included in this study and whether they are measured in the Kettunen and Davis GWAS (NA means not available).
TraitDescriptionKettunenDavis
VLDL traits and total triglycerides
TGTotal triglycerides
VLDL-DVLDL diameter
XS-VLDL-LTotal lipids in very small VLDLNA
XS-VLDL-PConcentration of very small VLDL particles
XS-VLDL-PLPhospholipids in very small VLDL
XS-VLDL-TGTriglycerides in very small VLDL
S-VLDL-CTotal cholesterol in small VLDL
S-VLDL-FCFree cholesterol in small VLDL
S-VLDL-LTotal lipids in small VLDLNA
S-VLDL-PConcentration of small VLDL particles
S-VLDL-PLPhospholipids in small VLDL
S-VLDL-TGTriglycerides in small VLDL
M-VLDL-CTotal cholesterol in medium VLDL
M-VLDL-CECholesterol esters in medium VLDL
M-VLDL-FCFree cholesterol in medium VLDL
M-VLDL-LTotal lipids in medium VLDLNA
M-VLDL-PConcentration of medium VLDL particles
M-VLDL-PLPhospholipids in medium VLDL
M-VLDL-TGTriglycerides in medium VLDL
L-VLDL-CTotal cholesterol in large VLDL
L-VLDL-CECholesterol esters in large VLDL
L-VLDL-FCFree cholesterol in large VLDL
L-VLDL-LTotal lipids in large VLDLNA
L-VLDL-PConcentration of large VLDL particles
L-VLDL-PLPhospholipids in large VLDL
L-VLDL-TGTriglycerides in large VLDL
XL-VLDL-LTotal lipids in very large VLDLNA
XL-VLDL-PConcentration of very large VLDL particles
XL-VLDL-PLPhospholipids in very large VLDL
XL-VLDL-TGTriglycerides in very large VLDL
XXL-VLDL-LTotal lipids in chylomicrons and extremely very large VLDLNA
XXL-VLDL-PConcentration of chylomicrons and extremely very large VLDL particles
XXL-VLDL-PLPhospholipids in chylomicrons and extremely very large
XXL-VLDL-TGTriglycerides in chylomicrons and extremely very large
LDL and IDL traits
LDL-CTotal cholesterol in LDL
ApoBApolipoprotein B
LDL-DLDL diameter
S-LDL-CTotal cholesterol in small LDL
S-LDL-LTotal lipids in small LDLNA
S-LDL-PPhospholipids in small LDL
M-LDL-CTotal cholesterol in medium LDL
M-LDL-CECholesterol esters in medium LDL
M-LDL-LTotal lipids in medium LDLNA
M-LDL-PConcentration of medium LDL particles
M-LDL-PLPhospholipids in medium LDL
L-LDL-CTotal cholesterol in large LDL
L-LDL-CECholesterol esters in large LDL
L-LDL-FCFree cholesterol in large LDL
L-LDL-LTotal lipids in large LDLNA
L-LDL-PConcentration of large LDL particles
L-LDL-PLPhospholipids in large LDL
IDL-CTotal cholesterol in IDL
IDL-FCFree cholesterol in IDL
IDL-LTotal lipids in IDLNA
IDL-PConcentration of IDL particles
IDL-PLPhospholipids in IDL
IDL-TGTriglycerides in IDL
HDL traits
HDL-CTotal cholesterol in HDL
ApoA1Apolipoprotein A1
HDL-DHDL diameter
S-HDL-LTotal lipids in small HDLNA
S-HDL-PConcentration of small HDL particles
S-HDL-TGTriglycerides in small HDL
M-HDL-CTotal cholesterol in medium HDL
M-HDL-CECholesterol esters in medium HDL
M-HDL-FCFree cholesterol in medium HDL
M-HDL-LTotal lipids in medium HDLNA
M-HDL-PConcentration of medium HDL particles
M-HDL-PLPhospholipids in medium HDL
L-HDL-CTotal cholesterol in large HDL
L-HDL-CECholesterol esters in large HDL
L-HDL-FCFree cholesterol in large HDL
L-HDL-LTotal lipids in large HDLNA
L-HDL-PConcentration of large HDL particles
L-HDL-PLPhospholipids in large HDL
XL-HDL-CTotal cholesterol in very large HDL
XL-HDL-CECholesterol esters in very large HDL
XL-HDL-FCFree cholesterol in very large HDL
XL-HDL-LTotal lipids in very large HDLNA
XL-HDL-PConcentration of very large HDL particles
XL-HDL-PLPhospholipids in very large HDL
XL-HDL-TGTriglycerides in very large HDL

Appendix 2

Genetic correlations

We estimated the genetic correlation between lipoprotein subfractions, particle sizes, and traditional lipid risk factors using the LD score regression (Li et al., 2016). Appendix 2—figure 13 show the estimated genetic correlation matrix between selected traits using different datasets. Below the figures, Appendix 2—table 1 shows the estimated genetic correlations of the lipoprotein subbfractions with the traditional lipid risk factors using the Davis GWAS. The results in Appendix 2—table 1 were then used to screen the traits as described in Materials and methods.

Appendix 2—figure 1
Genetic correlations computed using the Davis et al., 2017 GWAS summary dataset.
Appendix 2—figure 2
Genetic correlations computed using the Kettunen et al., 2016 GWAS summary dataset.
Appendix 2—figure 3
Genetic correlations computed by meta-analyzing the results in Appendix 2—figures 1 and 2.
Appendix 2—table 1
Estimated genetic correlation (standard error) of the lipoprotein subfractions with the traditional lipid risk factors using the Davis GWAS.

Bolded estimates are above 0.8 and the corresponding traits were removed in phenotypic screening.

TraitApoA1ApoBHDL-CLDL-CTG
S-HDL-L0.31 (0.28)0.34 (0.25)0.13 (0.26)0.27 (0.3)0.2 (0.22)
S-HDL-P0.36 (0.24)0.27 (0.22)−0.01 (0.22)0.1 (0.31)0.48 (0.17)
S-HDL-TG−0.13 (0.25)0.77 (0.13)−0.66 (0.15)0.13 (0.28)1.03 (0.07)
M-HDL-C0.65 (0.14)−0.18 (0.2)0.81 (0.09)−0.09 (0.25)−0.34 (0.17)
M-HDL-CE0.68 (0.14)−0.23 (0.21)0.57 (0.12)−0.24 (0.24)−0.32 (0.18)
M-HDL-FC0.67 (0.12)−0.08 (0.21)0.83 (0.08)0.04 (0.24)−0.28 (0.18)
M-HDL-L0.71 (0.15)0.02 (0.27)0.52 (0.17)−0.03 (0.29)−0.19 (0.25)
M-HDL-P0.75 (0.12)0.15 (0.23)0.46 (0.14)0.08 (0.26)0 (0.19)
M-HDL-PL0.69 (0.13)0.04 (0.22)0.65 (0.11)0.02 (0.25)−0.04 (0.19)
L-HDL-C0.76 (0.11)−0.42 (0.13)0.95 (0.02)−0.1 (0.18)−0.62 (0.09)
L-HDL-CE0.82 (0.1)−0.4 (0.12)0.93 (0.04)−0.16 (0.17)−0.62 (0.09)
L-HDL-FC0.66 (0.12)−0.46 (0.13)0.92 (0.03)−0.13 (0.18)−0.7 (0.08)
L-HDL-L0.81 (0.11)−0.29 (0.15)0.74 (0.07)−0.15 (0.18)−0.56 (0.12)
L-HDL-P0.79 (0.09)−0.35 (0.13)0.82 (0.05)−0.12 (0.16)−0.61 (0.09)
L-HDL-PL0.77 (0.09)−0.34 (0.13)0.79 (0.05)−0.12 (0.17)−0.61 (0.09)
XL-HDL-C0.75 (0.16)−0.25 (0.19)0.9 (0.1)0.4 (0.27)−0.63 (0.13)
XL-HDL-CE0.82 (0.16)−0.17 (0.19)0.82 (0.09)0.41 (0.27)−0.54 (0.12)
XL-HDL-FC0.72 (0.14)−0.37 (0.18)0.94 (0.08)0.17 (0.23)−0.71 (0.11)
XL-HDL-L0.93 (0.16)−0.08 (0.25)0.68 (0.14)0.1 (0.27)−0.35 (0.2)
XL-HDL-P0.81 (0.13)−0.32 (0.16)0.86 (0.08)0.17 (0.21)−0.69 (0.11)
XL-HDL-PL0.76 (0.12)−0.41 (0.15)0.83 (0.07)−0.09 (0.18)−0.7 (0.09)
XL-HDL-TG0.72 (0.13)0.49 (0.17)0.33 (0.13)0.13 (0.26)0.3 (0.15)
HDL-D0.7 (0.11)−0.36 (0.13)0.8 (0.06)−0.08 (0.17)−0.64 (0.09)
IDL-C0.38 (0.21)0.58 (0.19)0.07 (0.19)0.8 (0.14)0.39 (0.17)
IDL-FC0.23 (0.2)0.78 (0.12)−0.05 (0.17)0.61 (0.19)0.44 (0.15)
IDL-L0.38 (0.23)0.65 (0.18)0.05 (0.2)0.64 (0.2)0.47 (0.17)
IDL-P0.31 (0.2)0.66 (0.14)−0.04 (0.17)0.82 (0.13)0.49 (0.14)
IDL-PL0.25 (0.23)0.83 (0.1)−0.12 (0.19)0.7 (0.19)0.64 (0.15)
IDL-TG0.22 (0.18)0.82 (0.08)−0.2 (0.13)0.56 (0.15)0.67 (0.08)
S-LDL-C0.11 (0.28)0.66 (0.18)−0.16 (0.22)0.44 (0.34)0.58 (0.14)
S-LDL-L0.26 (0.23)0.66 (0.17)−0.06 (0.21)0.62 (0.21)0.58 (0.13)
S-LDL-P0.34 (0.2)0.68 (0.15)−0.02 (0.19)0.63 (0.18)0.58 (0.13)
M-LDL-C0.15 (0.26)0.63 (0.18)0.22 (0.22)0.87 (0.08)0.13 (0.23)
M-LDL-CE0.3 (0.23)0.61 (0.2)0.05 (0.21)0.65 (0.2)0.45 (0.16)
M-LDL-L0.29 (0.22)0.63 (0.18)0.01 (0.21)0.66 (0.19)0.5 (0.15)
M-LDL-P0.29 (0.23)0.63 (0.18)−0.01 (0.21)0.65 (0.21)0.51 (0.15)
M-LDL-PL0.2 (0.24)0.69 (0.16)0.11 (0.2)0.89 (0.06)0.18 (0.22)
L-LDL-C0.25 (0.24)0.58 (0.21)0.25 (0.22)0.68 (0.19)0.23 (0.21)
L-LDL-CE0.3 (0.23)0.58 (0.22)0.05 (0.21)0.65 (0.21)0.41 (0.17)
L-LDL-FC0.31 (0.24)0.57 (0.22)0.33 (0.23)0.7 (0.18)0.13 (0.23)
L-LDL-L0.31 (0.23)0.61 (0.2)0.04 (0.21)0.65 (0.21)0.44 (0.17)
L-LDL-P0.31 (0.23)0.63 (0.19)0.02 (0.21)0.65 (0.21)0.47 (0.16)
L-LDL-PL0.27 (0.25)0.61 (0.2)0.24 (0.22)0.67 (0.2)0.27 (0.2)
LDL-D−0.33 (0.25)−0.22 (0.23)−0.15 (0.21)−0.15 (0.29)−0.37 (0.16)
XS-VLDL-L0.25 (0.23)0.8 (0.08)−0.2 (0.17)0.61 (0.14)0.73 (0.09)
XS-VLDL-P0.17 (0.18)0.83 (0.07)−0.26 (0.13)0.57 (0.13)0.71 (0.07)
XS-VLDL-PL0.21 (0.19)0.78 (0.09)−0.15 (0.15)0.74 (0.14)0.57 (0.11)
XS-VLDL-TG0.06 (0.18)0.83 (0.08)−0.37 (0.11)0.56 (0.13)0.85 (0.04)
S-VLDL-FC−0.08 (0.2)0.94 (0.05)−0.49 (0.12)0.59 (0.12)0.92 (0.03)
S-VLDL-L−0.12 (0.24)0.7 (0.08)−0.46 (0.15)0.5 (0.14)0.8 (0.05)
S-VLDL-P−0.09 (0.19)0.78 (0.07)−0.48 (0.11)0.5 (0.14)0.95 (0.02)
S-VLDL-PL−0.03 (0.2)0.82 (0.08)−0.43 (0.12)0.44 (0.17)0.92 (0.03)
S-VLDL-TG−0.1 (0.2)0.9 (0.08)−0.49 (0.11)0.49 (0.15)0.98 (0.01)
S-VLDL-C0.01 (0.2)0.9 (0.06)−0.39 (0.13)0.61 (0.15)0.89 (0.05)
M-VLDL-C−0.01 (0.2)0.8 (0.09)−0.47 (0.12)0.41 (0.18)0.95 (0.02)
M-VLDL-CE0.01 (0.19)0.78 (0.08)−0.43 (0.12)0.5 (0.15)0.9 (0.03)
M-VLDL-FC0 (0.21)0.83 (0.09)−0.48 (0.12)0.4 (0.18)0.97 (0.01)
M-VLDL-L−0.1 (0.24)0.66 (0.11)−0.48 (0.15)0.4 (0.18)0.8 (0.05)
M-VLDL-P−0.06 (0.19)0.78 (0.1)−0.46 (0.12)0.43 (0.16)0.98 (0.02)
M-VLDL-PL0.03 (0.21)0.85 (0.09)−0.48 (0.12)0.4 (0.18)0.98 (0.01)
M-VLDL-TG−0.02 (0.21)0.82 (0.11)−0.5 (0.13)0.33 (0.19)0.98 (0.02)
L-VLDL-C−0.05 (0.2)0.83 (0.12)−0.55 (0.12)0.36 (0.19)1 (0.02)
L-VLDL-CE0 (0.19)0.78 (0.12)−0.44 (0.12)0.43 (0.19)0.93 (0.03)
L-VLDL-FC−0.03 (0.2)0.84 (0.12)−0.53 (0.13)0.36 (0.19)1 (0.02)
L-VLDL-L−0.06 (0.24)0.66 (0.14)−0.47 (0.16)0.36 (0.2)0.86 (0.05)
L-VLDL-P−0.02 (0.21)0.72 (0.12)−0.44 (0.13)0.33 (0.18)0.98 (0.02)
L-VLDL-PL0.01 (0.21)0.86 (0.12)−0.53 (0.13)0.3 (0.2)1.04 (0.03)
L-VLDL-TG−0.06 (0.21)0.78 (0.12)−0.54 (0.13)0.26 (0.19)1 (0.02)
XL-VLDL-L−0.08 (0.24)0.7 (0.15)−0.52 (0.16)0.43 (0.2)0.85 (0.05)
XL-VLDL-P−0.06 (0.2)0.76 (0.12)−0.48 (0.13)0.44 (0.18)0.95 (0.03)
XL-VLDL-PL−0.09 (0.23)0.82 (0.13)−0.62 (0.15)0.32 (0.21)1.06 (0.04)
XL-VLDL-TG−0.14 (0.21)0.86 (0.13)−0.65 (0.13)0.34 (0.19)1.03 (0.04)
XXL-VLDL-L−0.07 (0.25)0.65 (0.16)−0.5 (0.17)0.38 (0.22)0.83 (0.06)
XXL-VLDL-P0.17 (0.2)0.72 (0.15)−0.3 (0.15)0.39 (0.21)0.86 (0.07)
XXL-VLDL-PL−0.3 (0.24)0.66 (0.17)−0.8 (0.16)0.22 (0.21)1.06 (0.06)
XXL-VLDL-TG−0.21 (0.25)0.64 (0.16)−0.7 (0.15)0.22 (0.22)1.08 (0.05)
VLDL-D−0.22 (0.2)0.55 (0.14)−0.53 (0.12)0.12 (0.19)0.86 (0.04)

Appendix 3

Mendelian randomization

We implemented several Mendelian randomization (MR) designs and statistical methods to estimate the causal effect of lipoprotein subfractions and particles sizes on coronary artery disease. In general, we adopted the three-sample summary data MR design described in Zhao et al., 2019b, Wang et al., 2020 and we swapped the roles of the GWAS datasets whenever permitted by the statistical methods. More specifically, the statistical methods we used for univariable MR (RAPS, IVW, weighted median) require that the GWAS datasets for obtaining instruments, SNP effects on the exposure, and SNP effects on the outcome must have no overlapping sample. The multivariable MR method we used (GRAPPLE) allows the exposure and outcome GWAS to be dependent and estimates the proportion of overlapping sample. However, GRAPPLE still requires that the selection GWAS uses an non-overlapping sample.

The MR designs we implemented in this study are summarized in Appendix 3—table 1. We considered two ways of instrument selection for univariable MR. In ‘traditional selection’, the traditional lipid traits were used to select the instruments for the corresponding subfraction traits. That is, HDL-C was used to select SNPs for HDL subfractions and particle size, LDL-C for IDL and LDL subfractions and particle size, and TG for VLDL subfractions and particle size. This tends to select more instruments because the GWAS for traditional lipid traits had a larger sample size. In ‘subfraction selection’, the instrumental SNPs were selected for each lipoprotein subfraction and particle size using the same or closest trait in the selection GWAS. For example, if the exposure under investigation is S-HDL-L but it is not measured in the Davis GWAS (if it is used for selection), S-HDL-P is used instead for instrument selection.

For multivariable MR, we considered two models with different sets of exposures: TG, LDL-C, HDL-C, and the subfraction/particle size under investigation; TG, ApoB, ApoA1, and the subfraction/particle size under investigation. SNPs were selected as potential instruments if they were associated (p-value 10-4) with at least one of the four exposures. LD clumping was then used to obtain independent instruments, as described in Materials and Methods.

We briefly comment on the statistical methods used in univariable MR. All the three methods we used—RAPS, IVW, weighted median—require that the exposure GWAS and outcome GWAS have non-overlapping samples. RAPS and weighted median can provide consistent estimate of the causal effect even when some of the genetic variants are not valid instruments, provided that the direct effects of the genetic variants are independent of the strength of their associations with the exposure. The last condition is called the Instrument Strength Independent of Direct Effect (InSIDE) assumption in the MR literature [bowden2015mendelian]. RAPS is also robust to idiosyncratically large direct effect (Bowden et al., 2015). Because IVW and weighted median can be severely biased by weak instruments (Zhao et al., 2020), we only used them with the set of SNPs that have genome-wide significant association (p-value 5×10-8) with the exposure. In comparison, RAPS does not suffer from weak instrument bias and we used it with all the SNPs obtained by LD clumping without any p-value threshold.

Below, Appendix 3—figure 1 shows the MR results for the 27 lipoprotein measurements selected in phenotypic screening. Estimates that are statistically significant at a false discovery rate of 0.05 are shown in Figure 2 of the main paper. Appendix 3—table 2 shows the estimated effect of all the lipoprotein subfractions and particle sizes on myocardial infarction or coronary artery disease in various MR designs. Full results of the multivariable MR analyses, including the estimated effects of the traditional lipid risk factors, can be found in Appendix 3—tables 5 and 6. The results of the univariable MR analyses using IVW and weighted median estimators can be found in Appendix 3—tables 3 and 4.

Appendix 3—table 1
Three-sample Mendelian randomization designs.
MR designSelectionExposureOutcomeReported in
Univariable(traditional selection)GERADavisCARDIoGRAMplusC4DAppendix 3—table 24
GERADavisUK BiobankAppendix 3—table 24
GERAKettunenUK BiobankAppendix 3—table 24
GLGCDavisUK BiobankAppendix 3—table 24
Univariable(subfraction selection)DavisKettunenUK BiobankFigure 2; Appendix 3—figure 1 and Appendix 3—table 24
KettunenDavisUK BiobankAppendix 3—figure 1 and Appendix 3—table 24
MultivariableDavis, GERAKettunen, GLGCCARDIoGRAMplusC4D+ UK BiobankFigure 2, Table 2; Appendix 3—figure 1 and Appendix 3—table 24

Pooled results

Appendix 3—figure 1
Mendelian randomization results for the 27 lipoprotein measurements selected in phenotypic screening.

In the tables below, Red indicates p-value is significant (at level 0.05) after Bonferroni correction for all the results in the corresponding table and blue indicates p-value ≤ 0.05.

Appendix 3—table 2
Mendelian randomization results using all selected SNPs (univariable MR using RAPS and multivariable MR using GRAPPLE).
Method: RAPS/GRAPPLE + All SNPs
ScreeningGERAGERAGERAGLGCDavisKettunenGERA + DavisGERA + Davis
ExposureDavisDavisKettunenDavisKettunenDavisGLGC + KettunenGLGC + Kettunen
OutcomeCADUKBUKBUKBUKBUKBCAD + UKBCAD + UKB
AdjustedHDL-C + LDL-C + TGApoA1 + ApoB + TG
VLDL traits
TG0.258 (0.053)0.296 (0.075)NA0.262 (0.06)NA0.289 (0.068)NANA
VLDL-D-0.099 (0.049)0.028 (0.074)0.072 (0.073)0.116 (0.065)-0.163 (0.067)-0.204 (0.071)-0.588 (0.094)-0.32 (0.112)
XS-VLDL-LNANA0.368 (0.064)NA0.429 (0.059)NA0.132 (0.119)0.084 (0.141)
XS-VLDL-P0.17 (0.031)0.26 (0.048)0.367 (0.065)0.248 (0.047)0.429 (0.06)0.338 (0.056)0.118 (0.125)0.061 (0.158)
XS-VLDL-PL0.191 (0.034)0.284 (0.055)0.386 (0.069)0.278 (0.052)0.449 (0.049)0.435 (0.049)0.159 (0.12)0.253 (0.135)
XS-VLDL-TG0.201 (0.034)0.3 (0.053)0.388 (0.068)0.283 (0.046)0.372 (0.063)0.326 (0.055)-0.157 (0.187)-0.248 (0.15)
S-VLDL-C0.294 (0.06)0.343 (0.076)NA0.322 (0.063)NA0.424 (0.094)-1.035 (0.323)-1.265 (0.568)
S-VLDL-FC0.243 (0.051)0.303 (0.068)0.389 (0.079)0.286 (0.056)0.489 (0.071)0.416 (0.074)-1.027 (0.337)-0.489 (0.213)
S-VLDL-LNANA0.356 (0.075)NA0.376 (0.072)NA-0.898 (0.28)-1.629 (0.586)
S-VLDL-P0.226 (0.047)0.288 (0.068)0.343 (0.074)0.261 (0.054)0.359 (0.069)0.271 (0.094)-1.245 (0.463)-1.644 (0.606)
S-VLDL-PL0.228 (0.047)0.294 (0.067)0.372 (0.074)0.273 (0.054)0.365 (0.066)0.336 (0.063)-0.613 (0.182)-1.213 (0.478)
S-VLDL-TG0.223 (0.049)0.283 (0.071)0.323 (0.073)0.25 (0.055)0.327 (0.071)0.275 (0.067)NaN-0.301 (0.108)
M-VLDL-C0.253 (0.053)0.304 (0.078)0.327 (0.074)0.276 (0.06)0.368 (0.07)0.312 (0.079)-1.433 (0.451)-0.373 (0.118)
M-VLDL-CE0.248 (0.051)0.309 (0.074)0.344 (0.077)0.285 (0.058)0.369 (0.073)0.295 (0.069)-1.035 (0.293)-0.995 (0.338)
M-VLDL-FC0.245 (0.058)0.283 (0.082)0.31 (0.076)0.259 (0.063)0.341 (0.069)0.341 (0.068)-1.412 (0.444)-0.799 (0.311)
M-VLDL-LNANA0.311 (0.079)NA0.358 (0.078)NA-1.878 (0.75)-0.298 (0.098)
M-VLDL-P0.25 (0.062)0.282 (0.083)0.305 (0.081)0.247 (0.065)0.293 (0.089)0.269 (0.065)-1.974 (0.745)-0.312 (0.096)
M-VLDL-PL0.248 (0.056)0.295 (0.077)0.318 (0.075)0.259 (0.06)0.351 (0.071)0.31 (0.063)-2.012 (0.943)-0.297 (0.106)
M-VLDL-TG0.205 (0.064)0.248 (0.087)0.3 (0.082)0.224 (0.067)0.275 (0.092)0.246 (0.074)-2.133 (0.879)-0.806 (0.455)
L-VLDL-C0.299 (0.067)0.304 (0.1)0.297 (0.081)0.291 (0.077)0.289 (0.085)0.317 (0.077)-1.254 (0.297)-0.609 (0.337)
L-VLDL-CE0.247 (0.061)0.282 (0.088)0.282 (0.082)0.282 (0.072)0.285 (0.082)0.3 (0.112)-1.081 (0.282)-0.673 (0.217)
L-VLDL-FC0.316 (0.076)0.294 (0.108)0.311 (0.083)0.287 (0.081)0.351 (0.087)0.298 (0.078)-1.274 (0.308)-0.619 (0.291)
L-VLDL-LNANA0.36 (0.096)NA0.32 (0.102)NA-1.277 (0.313)-0.532 (0.278)
L-VLDL-P0.268 (0.073)0.287 (0.103)0.281 (0.085)0.262 (0.075)0.219 (0.086)0.255 (0.082)-1.357 (0.344)-0.617 (0.229)
L-VLDL-PL0.322 (0.071)0.318 (0.102)0.346 (0.089)0.283 (0.077)0.397 (0.101)0.351 (0.076)NaN-0.287 (0.104)
L-VLDL-TG0.243 (0.077)0.238 (0.104)0.332 (0.094)0.246 (0.08)0.26 (0.103)0.324 (0.082)-1.428 (0.372)-0.252 (0.091)
XL-VLDL-LNANA0.289 (0.098)NA0.435 (0.14)NA-1.069 (0.203)-0.577 (0.249)
XL-VLDL-P0.27 (0.074)0.262 (0.099)0.281 (0.093)0.279 (0.084)0.404 (0.122)0.251 (0.084)-1.209 (0.238)-0.373 (0.109)
XL-VLDL-PL0.446 (0.09)0.344 (0.13)0.31 (0.093)0.361 (0.118)0.375 (0.12)0.408 (0.102)-1.214 (0.257)-0.583 (0.268)
XL-VLDL-TG0.294 (0.092)0.229 (0.109)0.261 (0.094)0.284 (0.095)0.365 (0.111)0.319 (0.093)-1.071 (0.205)-0.603 (0.248)
XXL-VLDL-LNANA0.397 (0.108)NA0.312 (0.108)NA-1.355 (0.318)-0.402 (0.144)
XXL-VLDL-P0.308 (0.08)0.327 (0.096)0.378 (0.097)0.297 (0.088)0.32 (0.101)0.227 (0.073)-1.639 (0.502)-1.089 (0.449)
XXL-VLDL-PL0.338 (0.091)0.346 (0.103)0.342 (0.103)0.351 (0.103)0.282 (0.114)0.317 (0.086)-1.259 (0.262)-0.814 (0.344)
XXL-VLDL-TG0.384 (0.108)0.374 (0.124)0.348 (0.1)0.433 (0.121)0.304 (0.138)0.359 (0.18)-1.202 (0.262)-1.075 (0.402)
IDL/LDL traits
LDL-C0.523 (0.043)0.512 (0.053)0.514 (0.042)0.473 (0.055)0.435 (0.048)0.464 (0.048)NA0.319 (0.182)
ApoB0.605 (0.056)0.55 (0.062)0.551 (0.052)0.543 (0.069)0.61 (0.066)0.613 (0.06)-0.532 (0.191)NA
LDL-D0.271 (0.215)0.452 (0.299)2.064 (0.233)0.831 (0.684)0.328 (0.073)0.201 (0.055)0.145 (0.061)0.119 (0.071)
S-LDL-C0.624 (0.053)0.589 (0.061)0.539 (0.048)0.537 (0.067)0.474 (0.056)0.48 (0.05)-0.282 (0.152)0.08 (0.238)
S-LDL-LNANA0.561 (0.047)NA0.473 (0.057)NA-0.251 (0.145)-0.005 (0.29)
S-LDL-P0.621 (0.057)0.581 (0.065)0.56 (0.049)0.558 (0.073)0.459 (0.061)0.546 (0.063)-0.266 (0.151)-0.362 (0.596)
M-LDL-C0.648 (0.055)0.607 (0.062)0.545 (0.044)0.545 (0.068)0.455 (0.049)0.557 (0.054)-0.271 (0.162)-0.169 (0.909)
M-LDL-CE0.643 (0.056)0.601 (0.062)0.564 (0.042)0.545 (0.069)0.467 (0.05)0.55 (0.055)-0.088 (0.188)NaN
M-LDL-LNANA0.559 (0.042)NA0.461 (0.049)NA-0.069 (0.191)NaN
M-LDL-P0.638 (0.056)0.597 (0.062)0.557 (0.043)0.54 (0.069)0.472 (0.051)0.46 (0.05)-0.179 (0.174)0.432 (0.31)
M-LDL-PL0.658 (0.063)0.605 (0.067)0.556 (0.047)0.571 (0.077)0.506 (0.053)0.559 (0.057)-0.407 (0.162)-0.566 (0.839)
L-LDL-C0.627 (0.053)0.577 (0.059)0.515 (0.042)0.504 (0.063)0.465 (0.048)0.488 (0.052)-0.059 (0.261)NaN
L-LDL-CE0.638 (0.055)0.589 (0.06)0.555 (0.041)0.514 (0.065)0.463 (0.049)0.493 (0.054)0.116 (0.321)0.461 (0.213)
L-LDL-FC0.609 (0.051)0.557 (0.057)0.503 (0.041)0.491 (0.06)0.468 (0.047)0.457 (0.052)0.223 (0.315)NaN
L-LDL-LNANA0.543 (0.04)NA0.468 (0.047)NA0.167 (0.273)NaN
L-LDL-P0.606 (0.052)0.559 (0.058)0.545 (0.041)0.49 (0.062)0.484 (0.046)0.494 (0.048)0.084 (0.213)NaN
L-LDL-PL0.61 (0.053)0.558 (0.058)0.515 (0.043)0.492 (0.063)0.528 (0.048)0.502 (0.052)-0.036 (0.195)NaN
IDL-C0.596 (0.054)0.55 (0.059)0.562 (0.042)0.481 (0.064)0.511 (0.047)0.423 (0.051)0.192 (0.229)0.769 (0.501)
IDL-FC0.586 (0.054)0.539 (0.059)0.525 (0.044)0.494 (0.063)0.44 (0.044)0.402 (0.05)0.19 (0.156)0.33 (0.127)
IDL-LNANA0.57 (0.043)NA0.494 (0.048)NA0.148 (0.175)0.444 (0.328)
IDL-P0.566 (0.052)0.536 (0.059)0.575 (0.044)0.488 (0.065)0.434 (0.049)0.412 (0.051)0.153 (0.148)0.292 (0.173)
IDL-PL0.583 (0.052)0.533 (0.058)0.532 (0.045)0.489 (0.064)0.471 (0.047)0.396 (0.05)0.153 (0.18)0.406 (0.184)
IDL-TG0.603 (0.066)0.595 (0.075)0.658 (0.063)0.567 (0.085)0.432 (0.056)0.315 (0.053)0.11 (0.103)0.047 (0.135)
HDL traits
HDL-C-0.117 (0.031)-0.199 (0.045)-0.136 (0.055)-0.317 (0.052)-0.045 (0.059)-0.108 (0.05)NANaN
ApoA1-0.119 (0.042)-0.193 (0.06)0.023 (0.058)-0.264 (0.071)0.075 (0.064)-0.13 (0.068)-0.481 (0.271)NA
HDL-D-0.008 (0.027)-0.124 (0.041)0.004 (0.046)-0.092 (0.048)0.067 (0.045)0.007 (0.041)0.333 (0.114)0.296 (0.1)
S-HDL-LNANA-0.098 (0.095)NA-0.037 (0.085)NA-0.312 (0.106)-0.224 (0.087)
S-HDL-P-0.265 (0.084)-0.362 (0.113)-0.13 (0.092)-0.317 (0.119)-0.053 (0.081)-0.08 (0.094)-0.331 (0.095)-0.24 (0.083)
S-HDL-TG0.354 (0.072)0.386 (0.088)0.65 (0.089)0.475 (0.097)0.351 (0.087)0.283 (0.073)0.253 (0.637)-0.044 (0.466)
M-HDL-C-0.323 (0.058)-0.43 (0.079)-0.364 (0.085)-0.376 (0.091)-0.46 (0.104)-0.434 (0.075)-0.508 (0.165)-0.442 (0.143)
M-HDL-CE-0.333 (0.058)-0.458 (0.078)-0.372 (0.09)-0.385 (0.087)-0.542 (0.105)-0.443 (0.071)-0.487 (0.157)-0.413 (0.137)
M-HDL-FC-0.275 (0.065)-0.319 (0.08)-0.262 (0.083)-0.313 (0.092)-0.313 (0.094)-0.409 (0.082)-0.649 (0.225)-0.408 (0.166)
M-HDL-LNANA-0.311 (0.095)NA-0.474 (0.123)NA-0.606 (0.188)-0.485 (0.155)
M-HDL-P-0.298 (0.06)-0.394 (0.086)-0.273 (0.101)-0.373 (0.1)-0.565 (0.131)-0.307 (0.079)-0.694 (0.204)-0.472 (0.166)
M-HDL-PL-0.265 (0.058)-0.346 (0.083)-0.25 (0.09)-0.335 (0.096)-0.358 (0.104)-0.3 (0.072)-0.632 (0.191)-0.486 (0.171)
L-HDL-C-0.067 (0.03)-0.144 (0.044)-0.139 (0.051)-0.144 (0.05)-0.147 (0.052)-0.049 (0.045)0.516 (0.213)0.575 (0.204)
L-HDL-CE-0.063 (0.03)-0.144 (0.044)-0.116 (0.051)-0.149 (0.051)-0.134 (0.051)-0.094 (0.047)0.519 (0.23)0.61 (0.206)
L-HDL-FC-0.082 (0.03)-0.144 (0.045)-0.114 (0.053)-0.128 (0.053)-0.13 (0.051)-0.03 (0.047)0.518 (0.181)0.59 (0.148)
L-HDL-LNANA-0.108 (0.05)NA-0.132 (0.052)NA0.457 (0.189)0.541 (0.184)
L-HDL-P-0.071 (0.028)-0.146 (0.042)-0.111 (0.05)-0.13 (0.049)-0.083 (0.05)-0.1 (0.043)0.422 (0.191)0.476 (0.155)
L-HDL-PL-0.087 (0.029)-0.161 (0.043)-0.141 (0.051)-0.142 (0.051)-0.105 (0.053)-0.092 (0.044)0.443 (0.202)0.51 (0.169)
XL-HDL-C0.055 (0.046)-0.013 (0.068)0.11 (0.066)0.064 (0.073)0.048 (0.069)0.112 (0.068)0.474 (0.223)0.565 (0.196)
XL-HDL-CE0.064 (0.044)0.006 (0.066)0.129 (0.066)0.08 (0.07)0.057 (0.068)0.046 (0.075)0.426 (0.177)0.511 (0.206)
XL-HDL-FC0.009 (0.039)-0.05 (0.059)0.066 (0.058)-0.026 (0.067)0.102 (0.06)0.049 (0.066)0.433 (0.16)0.609 (0.159)
XL-HDL-LNANA0.073 (0.055)NA0.038 (0.058)NA0.358 (0.154)0.481 (0.141)
XL-HDL-P0.038 (0.033)-0.022 (0.049)0.112 (0.057)0.017 (0.056)0.083 (0.055)0.023 (0.057)0.41 (0.139)0.39 (0.135)
XL-HDL-PL0.029 (0.031)-0.031 (0.046)0.037 (0.05)0.005 (0.055)0.038 (0.052)0.013 (0.046)0.343 (0.118)0.466 (0.12)
XL-HDL-TG0.092 (0.027)0.112 (0.041)0.14 (0.047)0.135 (0.047)0.191 (0.042)0.136 (0.039)0.147 (0.074)0.165 (0.086)

Univariable MR results

Appendix 3—table 3
Mendelian randomization results using genome-wide significant SNPs and inverse variance weighted (IVW) estimator.
Method: IVW + Significant SNPs
SelectionGERAGERAGERAGLGCDavisKettunen
ExposureDavisDavisKettunenDavisKettunenDavis
OutcomeCADUKBUKBUKBUKBUKB
VLDL traits
TG0.184 (0.051)0.278 (0.076)NA0.309 (0.074)NA0.207 (0.064)
VLDL-D0.044 (0.06)0.052 (0.09)0.038 (0.102)0.118 (0.091)-0.083 (0.16)-0.083 (0.138)
XS-VLDL-LNANA0.353 (0.08)NA0.372 (0.083)NA
XS-VLDL-P0.162 (0.04)0.256 (0.059)0.352 (0.081)0.273 (0.063)0.374 (0.084)0.373 (0.095)
XS-VLDL-PL0.165 (0.046)0.262 (0.069)0.37 (0.088)0.27 (0.075)0.443 (0.048)0.401 (0.07)
XS-VLDL-TG0.179 (0.041)0.277 (0.061)0.362 (0.082)0.288 (0.062)0.335 (0.076)0.314 (0.08)
S-VLDL-C0.237 (0.053)0.343 (0.08)NA0.339 (0.083)NA0.443 (0.116)
S-VLDL-FC0.21 (0.05)0.307 (0.076)0.344 (0.098)0.314 (0.076)0.262 (0.122)0.397 (0.116)
S-VLDL-LNANA0.318 (0.095)NA0.27 (0.106)NA
S-VLDL-P0.188 (0.049)0.274 (0.074)0.311 (0.093)0.29 (0.072)0.266 (0.103)0.331 (0.142)
S-VLDL-PL0.198 (0.048)0.291 (0.072)0.342 (0.091)0.3 (0.072)0.281 (0.089)0.331 (0.125)
S-VLDL-TG0.174 (0.051)0.255 (0.076)0.296 (0.094)0.28 (0.073)0.261 (0.102)0.262 (0.093)
M-VLDL-C0.188 (0.053)0.265 (0.08)0.305 (0.096)0.287 (0.077)0.361 (0.078)0.32 (0.134)
M-VLDL-CE0.203 (0.051)0.285 (0.077)0.32 (0.098)0.295 (0.076)0.264 (0.094)0.291 (0.125)
M-VLDL-FC0.165 (0.056)0.233 (0.084)0.292 (0.098)0.27 (0.08)0.3 (0.084)0.303 (0.104)
M-VLDL-LNANA0.265 (0.104)NA0.357 (0.096)NA
M-VLDL-P0.153 (0.056)0.214 (0.085)0.276 (0.104)0.258 (0.081)0.322 (0.092)0.268 (0.074)
M-VLDL-PL0.163 (0.054)0.23 (0.082)0.296 (0.097)0.266 (0.078)0.302 (0.084)0.289 (0.095)
M-VLDL-TG0.14 (0.058)0.196 (0.087)0.268 (0.107)0.247 (0.083)0.327 (0.093)0.245 (0.091)
L-VLDL-C0.177 (0.06)0.24 (0.091)0.288 (0.106)0.286 (0.089)0.108 (0.223)0.31 (0.084)
L-VLDL-CE0.178 (0.057)0.245 (0.087)0.262 (0.105)0.279 (0.086)0.182 (0.187)0.299 (0.077)
L-VLDL-FC0.176 (0.063)0.242 (0.094)0.295 (0.108)0.298 (0.091)0.321 (0.101)0.314 (0.082)
L-VLDL-LNANA0.291 (0.119)NA0.125 (0.232)NA
L-VLDL-P0.164 (0.062)0.227 (0.093)0.269 (0.108)0.275 (0.09)0.332 (0.127)0.247 (0.076)
L-VLDL-PL0.173 (0.061)0.23 (0.092)0.308 (0.115)0.284 (0.088)0.32 (0.127)0.302 (0.079)
L-VLDL-TG0.149 (0.063)0.202 (0.095)0.268 (0.118)0.267 (0.092)0.33 (0.131)0.302 (0.08)
XL-VLDL-LNANA0.263 (0.123)NA0.365 (0.286)NA
XL-VLDL-P0.149 (0.063)0.206 (0.095)0.247 (0.122)0.268 (0.096)0.346 (0.28)0.245 (0.077)
XL-VLDL-PL0.176 (0.067)0.243 (0.101)0.292 (0.119)0.323 (0.101)0.333 (0.265)0.344 (0.133)
XL-VLDL-TG0.151 (0.066)0.205 (0.1)0.241 (0.12)0.282 (0.1)0.323 (0.272)0.249 (0.081)
XXL-VLDL-LNANA0.356 (0.127)NA-0.165 (0.425)NA
XXL-VLDL-P0.228 (0.067)0.35 (0.099)0.372 (0.119)0.376 (0.098)-0.12 (0.389)0.006 (0.153)
XXL-VLDL-PL0.211 (0.07)0.31 (0.105)0.275 (0.125)0.399 (0.107)-0.145 (0.395)0.071 (0.191)
XXL-VLDL-TG0.221 (0.067)0.3 (0.102)0.292 (0.126)0.415 (0.104)0.09 (0.36)0.349 (0.303)
IDL/LDL traits
LDL-C0.427 (0.049)0.431 (0.054)0.409 (0.077)0.409 (0.054)0.416 (0.099)0.422 (0.063)
ApoB0.506 (0.058)0.525 (0.065)0.474 (0.093)0.473 (0.064)0.636 (0.092)0.569 (0.071)
LDL-D0.217 (0.151)0.423 (0.161)1.121 (0.178)0.271 (0.143)0.309 (0.126)0.211 (0.081)
S-LDL-C0.481 (0.056)0.467 (0.063)0.445 (0.087)0.438 (0.063)0.44 (0.128)0.436 (0.076)
S-LDL-LNANA0.44 (0.09)NA0.456 (0.132)NA
S-LDL-P0.501 (0.059)0.494 (0.068)0.449 (0.093)0.472 (0.067)0.49 (0.139)0.588 (0.097)
M-LDL-C0.475 (0.057)0.457 (0.064)0.426 (0.08)0.427 (0.064)0.418 (0.111)0.436 (0.087)
M-LDL-CE0.485 (0.058)0.47 (0.065)0.432 (0.078)0.436 (0.064)0.43 (0.107)0.444 (0.085)
M-LDL-LNANA0.43 (0.08)NA0.43 (0.11)NA
M-LDL-P0.479 (0.057)0.465 (0.064)0.437 (0.081)0.44 (0.064)0.413 (0.122)0.439 (0.093)
M-LDL-PL0.5 (0.063)0.49 (0.071)0.437 (0.087)0.464 (0.07)0.443 (0.132)0.497 (0.099)
L-LDL-C0.449 (0.055)0.436 (0.061)0.432 (0.076)0.411 (0.061)0.409 (0.106)0.417 (0.076)
L-LDL-CE0.464 (0.056)0.451 (0.062)0.426 (0.075)0.422 (0.062)0.416 (0.102)0.433 (0.077)
L-LDL-FC0.425 (0.054)0.411 (0.059)0.424 (0.074)0.393 (0.059)0.387 (0.105)0.394 (0.078)
L-LDL-LNANA0.427 (0.074)NA0.407 (0.103)NA
L-LDL-P0.448 (0.054)0.442 (0.06)0.435 (0.075)0.421 (0.059)0.413 (0.104)0.424 (0.075)
L-LDL-PL0.444 (0.056)0.438 (0.061)0.441 (0.078)0.423 (0.061)0.42 (0.109)0.429 (0.076)
IDL-C0.447 (0.055)0.455 (0.059)0.451 (0.075)0.433 (0.06)0.439 (0.085)0.422 (0.07)
IDL-FC0.429 (0.055)0.439 (0.059)0.468 (0.075)0.414 (0.059)0.431 (0.081)0.402 (0.074)
IDL-LNANA0.467 (0.075)NA0.445 (0.085)NA
IDL-P0.443 (0.055)0.467 (0.06)0.48 (0.077)0.45 (0.059)0.446 (0.088)0.426 (0.071)
IDL-PL0.429 (0.055)0.443 (0.059)0.473 (0.078)0.427 (0.059)0.435 (0.092)0.407 (0.069)
IDL-TG0.461 (0.07)0.518 (0.076)0.625 (0.098)0.494 (0.073)0.342 (0.085)0.34 (0.123)
HDL traits
HDL-C-0.085 (0.044)-0.156 (0.057)-0.146 (0.085)-0.195 (0.06)-0.082 (0.159)-0.015 (0.109)
ApoA1-0.072 (0.054)-0.155 (0.071)-0.036 (0.09)-0.194 (0.074)0.001 (0.192)0.066 (0.158)
HDL-D-0.027 (0.042)-0.071 (0.058)-0.052 (0.073)-0.092 (0.063)0.073 (0.098)0.074 (0.074)
S-HDL-LNANA-0.064 (0.148)NA-0.033 (0.092)NA
S-HDL-P-0.117 (0.087)-0.172 (0.116)-0.13 (0.146)-0.298 (0.117)-0.033 (0.09)-0.115 (0.174)
S-HDL-TG0.224 (0.063)0.317 (0.082)0.496 (0.107)0.344 (0.085)0.334 (0.096)0.286 (0.17)
M-HDL-C-0.214 (0.062)-0.327 (0.078)-0.48 (0.111)-0.39 (0.079)-0.423 (0.175)-0.39 (0.159)
M-HDL-CE-0.227 (0.062)-0.338 (0.077)-0.497 (0.111)-0.4 (0.078)-0.435 (0.194)-0.341 (0.238)
M-HDL-FC-0.158 (0.065)-0.272 (0.084)-0.341 (0.117)-0.337 (0.085)-0.288 (0.218)-0.278 (0.144)
M-HDL-LNANA-0.436 (0.125)NA-0.514 (0.223)NA
M-HDL-P-0.172 (0.066)-0.292 (0.087)-0.414 (0.132)-0.361 (0.089)-0.386 (0.307)-0.18 (0.118)
M-HDL-PL-0.161 (0.064)-0.275 (0.085)-0.38 (0.126)-0.345 (0.087)-0.419 (0.301)-0.2 (0.099)
L-HDL-C-0.047 (0.044)-0.097 (0.059)-0.124 (0.08)-0.133 (0.063)0.022 (0.106)0.021 (0.105)
L-HDL-CE-0.049 (0.044)-0.098 (0.059)-0.12 (0.079)-0.137 (0.063)0.023 (0.112)0.004 (0.106)
L-HDL-FC-0.044 (0.046)-0.094 (0.062)-0.106 (0.082)-0.127 (0.067)0.038 (0.103)0.017 (0.109)
L-HDL-LNANA-0.106 (0.077)NA0.034 (0.102)NA
L-HDL-P-0.045 (0.043)-0.097 (0.058)-0.102 (0.077)-0.125 (0.063)0.009 (0.111)0.025 (0.11)
L-HDL-PL-0.054 (0.044)-0.11 (0.06)-0.115 (0.079)-0.14 (0.064)0.006 (0.115)0.016 (0.115)
XL-HDL-C0.03 (0.06)-0.012 (0.084)0.014 (0.099)-0.05 (0.088)-0.015 (0.165)0.161 (0.101)
XL-HDL-CE0.03 (0.059)-0.009 (0.081)0.025 (0.098)-0.042 (0.086)-0.001 (0.166)0.221 (0.107)
XL-HDL-FC-0.003 (0.056)-0.05 (0.076)-0.001 (0.089)-0.077 (0.081)0.072 (0.11)0.057 (0.092)
XL-HDL-LNANA0.001 (0.085)NA-0.009 (0.138)NA
XL-HDL-P0.015 (0.049)-0.021 (0.067)0.013 (0.088)-0.042 (0.071)0.103 (0.1)0.135 (0.093)
XL-HDL-PL0 (0.047)-0.037 (0.065)-0.026 (0.079)-0.055 (0.069)0.081 (0.088)0.071 (0.069)
XL-HDL-TG0.086 (0.041)0.103 (0.059)0.14 (0.075)0.13 (0.063)0.165 (0.043)0.126 (0.051)
Appendix 3—table 4
Mendelian randomization results using genome-wide significant SNPs and the weighted median estimator.
Method: Weighted median + Significant SNPs
SelectionGERAGERAGERAGLGCDavisKettunen
ExposureDavisDavisKettunenDavisKettunenDavis
OutcomeCADUKBUKBUKBUKBUKB
VLDL traits
TG0.042 (0.055)0.191 (0.072)NA0.228 (0.069)NA0.195 (0.077)
VLDL-D-0.098 (0.052)0.039 (0.095)0.057 (0.11)0.058 (0.093)-0.107 (0.099)-0.052 (0.115)
XS-VLDL-LNANA0.312 (0.076)NA0.393 (0.078)NA
XS-VLDL-P0.101 (0.037)0.23 (0.052)0.303 (0.079)0.229 (0.052)0.409 (0.08)0.253 (0.059)
XS-VLDL-PL0.096 (0.039)0.242 (0.059)0.352 (0.087)0.228 (0.06)0.422 (0.065)0.319 (0.062)
XS-VLDL-TG0.125 (0.041)0.266 (0.057)0.287 (0.079)0.221 (0.056)0.361 (0.084)0.306 (0.069)
S-VLDL-C0.187 (0.059)0.232 (0.075)NA0.256 (0.074)NA0.303 (0.094)
S-VLDL-FC0.152 (0.057)0.207 (0.069)0.289 (0.093)0.227 (0.069)0.316 (0.109)0.279 (0.077)
S-VLDL-LNANA0.282 (0.083)NA0.306 (0.099)NA
S-VLDL-P0.131 (0.057)0.202 (0.069)0.275 (0.085)0.221 (0.062)0.291 (0.093)0.226 (0.078)
S-VLDL-PL0.137 (0.053)0.205 (0.067)0.283 (0.083)0.218 (0.062)0.305 (0.092)0.263 (0.075)
S-VLDL-TG0.112 (0.057)0.204 (0.067)0.216 (0.088)0.229 (0.064)0.267 (0.099)0.244 (0.073)
M-VLDL-C0.12 (0.058)0.2 (0.07)0.255 (0.088)0.213 (0.066)0.303 (0.099)0.224 (0.081)
M-VLDL-CE0.144 (0.054)0.207 (0.071)0.262 (0.087)0.207 (0.068)0.301 (0.098)0.209 (0.072)
M-VLDL-FC0.081 (0.058)0.188 (0.074)0.221 (0.087)0.218 (0.068)0.272 (0.102)0.231 (0.08)
M-VLDL-LNANA0.227 (0.095)NA0.275 (0.109)NA
M-VLDL-P0.047 (0.06)0.191 (0.072)0.221 (0.096)0.226 (0.069)0.31 (0.104)0.257 (0.079)
M-VLDL-PL0.103 (0.056)0.197 (0.071)0.228 (0.089)0.217 (0.064)0.29 (0.104)0.231 (0.078)
M-VLDL-TG-0.005 (0.06)0.199 (0.075)0.224 (0.089)0.222 (0.068)0.318 (0.113)0.233 (0.085)
L-VLDL-C0.109 (0.068)0.2 (0.078)0.237 (0.093)0.231 (0.075)0.242 (0.122)0.262 (0.088)
L-VLDL-CE0.147 (0.063)0.211 (0.079)0.249 (0.09)0.253 (0.073)0.281 (0.11)0.286 (0.081)
L-VLDL-FC0.045 (0.065)0.199 (0.085)0.225 (0.093)0.224 (0.077)0.252 (0.125)0.228 (0.089)
L-VLDL-LNANA0.243 (0.102)NA0.261 (0.122)NA
L-VLDL-P0.041 (0.064)0.209 (0.082)0.224 (0.092)0.21 (0.079)0.289 (0.122)0.223 (0.086)
L-VLDL-PL0.08 (0.063)0.201 (0.08)0.244 (0.101)0.224 (0.077)0.278 (0.123)0.247 (0.092)
L-VLDL-TG-0.008 (0.061)0.215 (0.084)0.225 (0.103)0.161 (0.077)0.286 (0.13)0.277 (0.093)
XL-VLDL-LNANA0.262 (0.111)NANANA
XL-VLDL-P-0.026 (0.063)0.207 (0.091)0.289 (0.102)0.192 (0.088)NA0.209 (0.101)
XL-VLDL-PL-0.006 (0.067)0.197 (0.094)0.253 (0.094)0.213 (0.088)NA0.24 (0.101)
XL-VLDL-TG-0.026 (0.064)0.214 (0.092)0.229 (0.102)0.191 (0.088)NA0.212 (0.099)
XXL-VLDL-LNANA0.316 (0.114)NA-0.156 (0.22)NA
XXL-VLDL-P0.091 (0.071)0.236 (0.089)0.267 (0.1)0.263 (0.088)-0.104 (0.173)0.185 (0.098)
XXL-VLDL-PL0.153 (0.082)0.283 (0.096)0.267 (0.11)0.332 (0.095)-0.139 (0.178)0.126 (0.124)
XXL-VLDL-TG0.126 (0.078)0.266 (0.096)0.244 (0.108)0.339 (0.097)0.227 (0.171)0.23 (0.123)
IDL/LDL traits
LDL-C0.263 (0.053)0.307 (0.066)0.274 (0.05)0.297 (0.063)0.435 (0.072)0.431 (0.067)
ApoB0.365 (0.073)0.472 (0.078)0.381 (0.063)0.375 (0.081)0.624 (0.08)0.565 (0.094)
LDL-D0.306 (0.09)0.413 (0.157)0.467 (0.163)0.271 (0.142)0.294 (0.075)0.193 (0.06)
S-LDL-C0.271 (0.058)0.342 (0.073)0.343 (0.056)0.273 (0.068)0.498 (0.08)0.274 (0.083)
S-LDL-LNANA0.354 (0.061)NA0.449 (0.081)NA
S-LDL-P0.355 (0.063)0.366 (0.078)0.397 (0.069)0.329 (0.08)0.49 (0.089)0.581 (0.098)
M-LDL-C0.283 (0.055)0.313 (0.073)0.299 (0.05)0.244 (0.07)0.474 (0.074)0.297 (0.074)
M-LDL-CE0.27 (0.055)0.333 (0.077)0.299 (0.051)0.255 (0.071)0.437 (0.081)0.311 (0.077)
M-LDL-LNANA0.303 (0.053)NA0.432 (0.079)NA
M-LDL-P0.251 (0.057)0.32 (0.071)0.309 (0.054)0.278 (0.07)0.409 (0.072)0.325 (0.078)
M-LDL-PL0.343 (0.063)0.337 (0.081)0.316 (0.055)0.318 (0.078)0.457 (0.074)0.353 (0.085)
L-LDL-C0.251 (0.052)0.29 (0.067)0.303 (0.048)0.231 (0.063)0.45 (0.075)0.309 (0.071)
L-LDL-CE0.251 (0.054)0.32 (0.068)0.293 (0.052)0.241 (0.066)0.481 (0.074)0.322 (0.077)
L-LDL-FC0.251 (0.048)0.214 (0.061)0.301 (0.049)0.214 (0.062)0.427 (0.068)0.289 (0.065)
L-LDL-LNANA0.289 (0.051)NA0.412 (0.07)NA
L-LDL-P0.281 (0.053)0.321 (0.067)0.29 (0.053)0.244 (0.066)0.42 (0.072)0.351 (0.072)
L-LDL-PL0.286 (0.05)0.32 (0.067)0.313 (0.052)0.298 (0.065)0.413 (0.074)0.35 (0.076)
IDL-C0.283 (0.056)0.349 (0.068)0.315 (0.053)0.313 (0.07)0.51 (0.072)0.383 (0.068)
IDL-FC0.283 (0.053)0.334 (0.066)0.337 (0.053)0.314 (0.065)0.422 (0.067)0.367 (0.064)
IDL-LNANA0.329 (0.056)NA0.494 (0.069)NA
IDL-P0.331 (0.06)0.44 (0.067)0.343 (0.056)0.371 (0.069)0.463 (0.074)0.328 (0.068)
IDL-PL0.265 (0.055)0.332 (0.066)0.344 (0.056)0.316 (0.066)0.451 (0.072)0.359 (0.066)
IDL-TG0.233 (0.067)0.371 (0.086)0.605 (0.078)0.337 (0.085)0.315 (0.082)0.215 (0.057)
HDL traits
HDL-C-0.017 (0.04)-0.167 (0.058)-0.17 (0.072)-0.167 (0.058)-0.096 (0.077)-0.085 (0.07)
ApoA10.094 (0.049)-0.06 (0.076)-0.069 (0.087)-0.167 (0.07)0.005 (0.083)-0.051 (0.121)
HDL-D0.079 (0.034)0.062 (0.061)0.102 (0.064)0.088 (0.061)0.099 (0.061)0.096 (0.058)
S-HDL-LNANA-0.174 (0.113)NANANA
S-HDL-P-0.173 (0.069)0.018 (0.106)-0.171 (0.109)-0.235 (0.113)NA-0.049 (0.108)
S-HDL-TG0.157 (0.061)0.238 (0.085)0.312 (0.105)0.228 (0.086)0.327 (0.105)0.229 (0.076)
M-HDL-C-0.169 (0.054)-0.236 (0.082)-0.264 (0.097)-0.241 (0.077)-0.392 (0.098)-0.266 (0.084)
M-HDL-CE-0.166 (0.053)-0.23 (0.08)-0.271 (0.099)-0.238 (0.075)-0.394 (0.103)-0.23 (0.085)
M-HDL-FC-0.166 (0.055)-0.254 (0.086)-0.281 (0.098)-0.282 (0.087)-0.28 (0.102)-0.22 (0.1)
M-HDL-LNANA-0.296 (0.113)NA-0.448 (0.122)NA
M-HDL-P-0.157 (0.056)-0.199 (0.09)-0.298 (0.112)-0.231 (0.086)-0.291 (0.136)-0.165 (0.131)
M-HDL-PL-0.143 (0.058)-0.183 (0.088)-0.285 (0.108)-0.183 (0.085)-0.321 (0.114)-0.203 (0.12)
L-HDL-C0.086 (0.037)-0.009 (0.066)0.031 (0.083)-0.032 (0.08)0.003 (0.09)0.006 (0.068)
L-HDL-CE0.086 (0.038)-0.011 (0.067)0.075 (0.077)-0.037 (0.076)0.015 (0.091)-0.006 (0.068)
L-HDL-FC0.09 (0.039)-0.005 (0.067)0.079 (0.081)-0.019 (0.076)0.041 (0.078)0.027 (0.074)
L-HDL-LNANA0.074 (0.077)NA0.068 (0.084)NA
L-HDL-P0.081 (0.036)0.046 (0.062)0.075 (0.074)-0.01 (0.066)0.066 (0.07)0.078 (0.064)
L-HDL-PL0.084 (0.039)0 (0.067)0.051 (0.082)-0.021 (0.071)0.054 (0.075)0.074 (0.071)
XL-HDL-C0.163 (0.047)0.122 (0.091)0.136 (0.087)0.132 (0.09)0.02 (0.098)0.161 (0.096)
XL-HDL-CE0.139 (0.044)0.106 (0.088)0.122 (0.09)0.148 (0.085)0.038 (0.091)0.336 (0.092)
XL-HDL-FC0.135 (0.048)0.065 (0.079)0.133 (0.081)0.027 (0.077)0.159 (0.079)0.052 (0.086)
XL-HDL-LNANA0.119 (0.075)NA0.023 (0.078)NA
XL-HDL-P0.115 (0.035)0.087 (0.07)0.12 (0.073)0.129 (0.067)0.16 (0.071)0.15 (0.073)
XL-HDL-PL0.101 (0.037)0.064 (0.07)0.11 (0.072)0.121 (0.069)0.141 (0.069)0.088 (0.065)
XL-HDL-TG0.074 (0.027)0.107 (0.047)0.126 (0.051)0.118 (0.042)0.156 (0.05)0.114 (0.045)

Multivariable MR results

Appendix 3—table 5
Multivariable Mendelian randomization results (adjusted for HDL-C, LDL-C, and TG).
TraitHDL-CLDL-CTGSubfraction
VLDL traits
VLDL-D-0.251 (0.052)0.29 (0.037)0.6 (0.087)-0.588 (0.094)
XS-VLDL-L-0.086 (0.046)0.286 (0.077)0.089 (0.099)0.132 (0.119)
XS-VLDL-P-0.083 (0.045)0.299 (0.078)0.093 (0.106)0.118 (0.125)
XS-VLDL-PL-0.083 (0.046)0.249 (0.098)0.112 (0.076)0.159 (0.12)
XS-VLDL-TG-0.114 (0.046)0.463 (0.079)0.286 (0.173)-0.157 (0.187)
S-VLDL-C-0.267 (0.084)0.754 (0.112)1.033 (0.28)-1.035 (0.323)
S-VLDL-FC-0.195 (0.068)0.898 (0.163)0.935 (0.26)-1.027 (0.337)
S-VLDL-L-0.25 (0.072)0.755 (0.112)0.876 (0.233)-0.898 (0.28)
S-VLDL-P-0.31 (0.101)0.819 (0.157)1.209 (0.4)-1.245 (0.463)
S-VLDL-PL-0.168 (0.051)0.673 (0.074)0.626 (0.159)-0.613 (0.182)
S-VLDL-TG-0.499 (0.305)0.906 (0.34)2.532 (1.57)-2.628 (1.741)
M-VLDL-C-0.201 (0.068)0.808 (0.127)1.472 (0.424)-1.433 (0.451)
M-VLDL-CE-0.168 (0.061)0.799 (0.111)0.996 (0.249)-1.035 (0.293)
M-VLDL-FC-0.2 (0.072)0.658 (0.089)1.469 (0.417)-1.412 (0.444)
M-VLDL-L-0.355 (0.139)0.602 (0.096)1.787 (0.654)-1.878 (0.75)
M-VLDL-P-0.362 (0.124)0.569 (0.08)1.889 (0.676)-1.974 (0.745)
M-VLDL-PL-0.332 (0.141)0.722 (0.159)1.996 (0.869)-2.012 (0.943)
M-VLDL-TG-0.408 (0.153)0.432 (0.061)1.974 (0.772)-2.133 (0.879)
L-VLDL-C-0.216 (0.063)0.509 (0.046)1.163 (0.254)-1.254 (0.297)
L-VLDL-CE-0.272 (0.072)0.465 (0.04)1.038 (0.242)-1.081 (0.282)
L-VLDL-FC-0.144 (0.059)0.493 (0.044)1.233 (0.27)-1.274 (0.308)
L-VLDL-L-0.228 (0.066)0.414 (0.045)1.17 (0.263)-1.277 (0.313)
L-VLDL-P-0.115 (0.056)0.442 (0.046)1.351 (0.317)-1.357 (0.344)
L-VLDL-PL-0.221 (0.111)0.473 (0.07)2.135 (0.948)-2.316 (1.112)
L-VLDL-TG-0.196 (0.066)0.355 (0.05)1.357 (0.322)-1.428 (0.372)
XL-VLDL-L-0.126 (0.049)0.451 (0.04)0.896 (0.159)-1.069 (0.203)
XL-VLDL-P-0.127 (0.053)0.474 (0.043)1.038 (0.183)-1.209 (0.238)
XL-VLDL-PL-0.138 (0.055)0.5 (0.044)1.052 (0.204)-1.214 (0.257)
XL-VLDL-TG-0.129 (0.049)0.424 (0.04)0.944 (0.167)-1.071 (0.205)
XXL-VLDL-L-0.228 (0.067)0.444 (0.043)0.978 (0.207)-1.355 (0.318)
XXL-VLDL-P0.063 (0.076)0.452 (0.05)1.371 (0.384)-1.639 (0.502)
XXL-VLDL-PL-0.185 (0.056)0.371 (0.042)0.997 (0.185)-1.259 (0.262)
XXL-VLDL-TG-0.152 (0.059)0.41 (0.04)0.966 (0.19)-1.202 (0.262)
LDL/IDL traits
ApoB-0.084 (0.046)0.8 (0.146)0.427 (0.101)-0.532 (0.191)
LDL-D-0.057 (0.042)0.367 (0.03)0.21 (0.053)0.145 (0.061)
S-LDL-C-0.062 (0.043)0.614 (0.126)0.261 (0.062)-0.282 (0.152)
S-LDL-L-0.06 (0.044)0.584 (0.118)0.266 (0.068)-0.251 (0.145)
S-LDL-P-0.033 (0.047)0.589 (0.119)0.29 (0.078)-0.266 (0.151)
M-LDL-C-0.082 (0.044)0.623 (0.146)0.203 (0.054)-0.271 (0.162)
M-LDL-CE-0.074 (0.043)0.485 (0.167)0.169 (0.059)-0.088 (0.188)
M-LDL-L-0.071 (0.044)0.444 (0.171)0.19 (0.063)-0.069 (0.191)
M-LDL-P-0.054 (0.044)0.539 (0.153)0.213 (0.063)-0.179 (0.174)
M-LDL-PL-0.081 (0.045)0.747 (0.134)0.232 (0.062)-0.407 (0.162)
L-LDL-C-0.071 (0.049)0.437 (0.242)0.167 (0.054)-0.059 (0.261)
L-LDL-CE-0.07 (0.048)0.277 (0.301)0.149 (0.065)0.116 (0.321)
L-LDL-FC-0.112 (0.057)0.184 (0.304)0.163 (0.053)0.223 (0.315)
L-LDL-L-0.075 (0.049)0.229 (0.26)0.146 (0.068)0.167 (0.273)
L-LDL-P-0.083 (0.046)0.33 (0.2)0.128 (0.064)0.084 (0.213)
L-LDL-PL-0.101 (0.046)0.446 (0.177)0.155 (0.057)-0.036 (0.195)
IDL-C-0.108 (0.057)0.231 (0.215)0.128 (0.064)0.192 (0.229)
IDL-FC-0.107 (0.05)0.23 (0.147)0.123 (0.056)0.19 (0.156)
IDL-L-0.1 (0.05)0.274 (0.161)0.123 (0.069)0.148 (0.175)
IDL-P-0.101 (0.047)0.269 (0.134)0.109 (0.071)0.153 (0.148)
IDL-PL-0.076 (0.048)0.25 (0.162)0.134 (0.071)0.153 (0.18)
IDL-TG-0.083 (0.046)0.314 (0.069)0.103 (0.089)0.11 (0.103)
HDL traits
ApoA10.345 (0.25)0.544 (0.081)0.334 (0.109)-0.481 (0.271)
HDL-D-0.442 (0.124)0.421 (0.033)0.111 (0.055)0.333 (0.114)
S-HDL-L-0.117 (0.046)0.488 (0.044)0.189 (0.054)-0.312 (0.106)
S-HDL-P-0.112 (0.046)0.453 (0.035)0.225 (0.056)-0.331 (0.095)
S-HDL-TG0.002 (0.145)0.314 (0.156)-0.007 (0.469)0.253 (0.637)
M-HDL-C0.179 (0.097)0.36 (0.038)0.147 (0.054)-0.508 (0.165)
M-HDL-CE0.167 (0.087)0.319 (0.036)0.166 (0.055)-0.487 (0.157)
M-HDL-FC0.339 (0.141)0.436 (0.04)0.247 (0.059)-0.649 (0.225)
M-HDL-L0.27 (0.108)0.362 (0.032)0.299 (0.063)-0.606 (0.188)
M-HDL-P0.302 (0.112)0.386 (0.033)0.371 (0.075)-0.694 (0.204)
M-HDL-PL0.311 (0.117)0.402 (0.033)0.333 (0.07)-0.632 (0.191)
L-HDL-C-0.589 (0.211)0.469 (0.039)0.146 (0.055)0.516 (0.213)
L-HDL-CE-0.602 (0.239)0.477 (0.042)0.137 (0.056)0.519 (0.23)
L-HDL-FC-0.573 (0.177)0.437 (0.034)0.171 (0.054)0.518 (0.181)
L-HDL-L-0.556 (0.193)0.437 (0.034)0.142 (0.055)0.457 (0.189)
L-HDL-P-0.515 (0.198)0.417 (0.03)0.133 (0.056)0.422 (0.191)
L-HDL-PL-0.53 (0.201)0.415 (0.034)0.152 (0.055)0.443 (0.202)
XL-HDL-C-0.447 (0.182)0.342 (0.036)0.071 (0.079)0.474 (0.223)
XL-HDL-CE-0.425 (0.146)0.366 (0.038)0.051 (0.069)0.426 (0.177)
XL-HDL-FC-0.459 (0.147)0.377 (0.031)0.097 (0.062)0.433 (0.16)
XL-HDL-L-0.405 (0.146)0.364 (0.031)0.077 (0.068)0.358 (0.154)
XL-HDL-P-0.451 (0.134)0.374 (0.03)0.078 (0.064)0.41 (0.139)
XL-HDL-PL-0.422 (0.119)0.412 (0.033)0.115 (0.055)0.343 (0.118)
XL-HDL-TG-0.186 (0.073)0.336 (0.035)0.045 (0.086)0.147 (0.074)
Appendix 3—table 6
Multivariable Mendelian randomization results (adjusted for ApoA1, ApoB, and TG).
TraitApoA1ApoBTGSubfraction
VLDL traits
VLDL-D-0.227 (0.067)0.545 (0.092)0.208 (0.139)-0.32 (0.112)
XS-VLDL-L-0.123 (0.063)0.53 (0.163)-0.121 (0.085)0.084 (0.141)
XS-VLDL-P-0.121 (0.064)0.553 (0.17)-0.123 (0.088)0.061 (0.158)
XS-VLDL-PL-0.147 (0.066)0.273 (0.138)0.028 (0.05)0.253 (0.135)
XS-VLDL-TG-0.102 (0.06)0.762 (0.168)0.069 (0.055)-0.248 (0.15)
S-VLDL-C-0.384 (0.141)1.426 (0.354)0.606 (0.351)-1.265 (0.568)
S-VLDL-FC-0.188 (0.077)1.001 (0.235)0.081 (0.053)-0.489 (0.213)
S-VLDL-L-0.46 (0.146)1.776 (0.417)0.7 (0.316)-1.629 (0.586)
S-VLDL-P-0.494 (0.159)1.677 (0.386)0.825 (0.372)-1.644 (0.606)
S-VLDL-PL-0.262 (0.097)1.41 (0.343)0.532 (0.261)-1.213 (0.478)
S-VLDL-TG-0.18 (0.069)0.792 (0.121)0.078 (0.051)-0.301 (0.108)
M-VLDL-C-0.157 (0.062)0.867 (0.132)0.085 (0.051)-0.373 (0.118)
M-VLDL-CE-0.221 (0.069)1.224 (0.223)0.47 (0.21)-0.995 (0.338)
M-VLDL-FC-0.222 (0.074)0.902 (0.133)0.482 (0.251)-0.799 (0.311)
M-VLDL-L-0.174 (0.065)0.76 (0.104)0.073 (0.05)-0.298 (0.098)
M-VLDL-P-0.181 (0.065)0.764 (0.1)0.077 (0.051)-0.312 (0.096)
M-VLDL-PL-0.159 (0.065)0.776 (0.116)0.08 (0.051)-0.297 (0.106)
M-VLDL-TG-0.263 (0.106)0.724 (0.094)0.547 (0.406)-0.806 (0.455)
L-VLDL-C-0.218 (0.084)0.732 (0.101)0.352 (0.278)-0.609 (0.337)
L-VLDL-CE-0.293 (0.079)0.781 (0.096)0.405 (0.189)-0.673 (0.217)
L-VLDL-FC-0.197 (0.069)0.737 (0.094)0.365 (0.25)-0.619 (0.291)
L-VLDL-L-0.194 (0.071)0.666 (0.087)0.289 (0.234)-0.532 (0.278)
L-VLDL-P-0.184 (0.061)0.677 (0.086)0.415 (0.217)-0.617 (0.229)
L-VLDL-PL-0.155 (0.063)0.715 (0.095)0.075 (0.051)-0.287 (0.104)
L-VLDL-TG-0.154 (0.062)0.67 (0.083)0.073 (0.05)-0.252 (0.091)
XL-VLDL-L-0.186 (0.066)0.694 (0.088)0.263 (0.19)-0.577 (0.249)
XL-VLDL-P-0.167 (0.061)0.742 (0.088)0.075 (0.05)-0.373 (0.109)
XL-VLDL-PL-0.191 (0.068)0.712 (0.092)0.271 (0.197)-0.583 (0.268)
XL-VLDL-TG-0.195 (0.068)0.666 (0.087)0.334 (0.21)-0.603 (0.248)
XXL-VLDL-L-0.173 (0.066)0.732 (0.098)0.088 (0.052)-0.402 (0.144)
XXL-VLDL-P-0.071 (0.065)0.705 (0.097)0.607 (0.321)-1.089 (0.449)
XXL-VLDL-PL-0.244 (0.082)0.666 (0.091)0.414 (0.257)-0.814 (0.344)
XXL-VLDL-TG-0.3 (0.091)0.694 (0.095)0.627 (0.306)-1.075 (0.402)
IDL/LDL traits
LDL-C-0.119 (0.062)0.247 (0.167)0.066 (0.054)0.319 (0.182)
LDL-D-0.123 (0.06)0.544 (0.091)-0.036 (0.087)0.119 (0.071)
S-LDL-C-0.097 (0.06)0.438 (0.216)0.044 (0.051)0.08 (0.238)
S-LDL-L-0.097 (0.063)0.503 (0.268)0.043 (0.051)-0.005 (0.29)
S-LDL-P-0.059 (0.103)0.932 (0.597)-0.122 (0.112)-0.362 (0.596)
M-LDL-C-0.099 (0.065)0.78 (1.034)-0.172 (0.425)-0.169 (0.909)
M-LDL-CE-0.157 (0.128)-0.346 (2.587)0.195 (0.855)0.854 (2.221)
M-LDL-L-0.123 (0.095)0.247 (1.479)-0.001 (0.445)0.32 (1.293)
M-LDL-P-0.134 (0.07)0.13 (0.286)0.053 (0.052)0.432 (0.31)
M-LDL-PL-0.075 (0.077)1.165 (0.868)-0.248 (0.253)-0.566 (0.839)
L-LDL-C-0.855 (1.68)-5.337 (13.402)2.405 (5.735)5.257 (11.72)
L-LDL-CE-0.151 (0.065)0.129 (0.193)0.061 (0.052)0.461 (0.213)
L-LDL-FC-0.397 (0.219)-1.139 (1.395)0.786 (0.711)1.531 (1.189)
L-LDL-L-0.265 (0.148)-0.854 (1.42)0.41 (0.51)1.266 (1.188)
L-LDL-P-0.258 (0.153)-0.607 (1.225)0.276 (0.402)1.064 (1.029)
L-LDL-PL-0.312 (0.187)-0.741 (1.411)0.39 (0.518)1.227 (1.245)
IDL-C-0.3 (0.123)-0.334 (0.616)0.276 (0.254)0.769 (0.501)
IDL-FC-0.199 (0.069)0.247 (0.118)0.044 (0.049)0.33 (0.127)
IDL-L-0.215 (0.089)0.021 (0.409)0.101 (0.15)0.444 (0.328)
IDL-P-0.175 (0.075)0.214 (0.172)0.04 (0.051)0.292 (0.173)
IDL-PL-0.183 (0.07)0.159 (0.172)0.031 (0.049)0.406 (0.184)
IDL-TG-0.143 (0.075)0.565 (0.146)-0.119 (0.087)0.047 (0.135)
HDL traits
HDL-C-1.513 (1.109)0.982 (0.314)0.27 (0.291)1.446 (1.112)
HDL-D-0.457 (0.138)0.613 (0.073)0.056 (0.049)0.296 (0.1)
S-HDL-L-0.128 (0.059)0.524 (0.062)0.067 (0.05)-0.224 (0.087)
S-HDL-P-0.132 (0.059)0.531 (0.059)0.071 (0.05)-0.24 (0.083)
S-HDL-TG-0.11 (0.113)0.595 (0.221)-0.057 (0.297)-0.044 (0.466)
M-HDL-C0.091 (0.084)0.459 (0.101)-0.1 (0.083)-0.442 (0.143)
M-HDL-CE0.09 (0.078)0.291 (0.083)0.082 (0.05)-0.413 (0.137)
M-HDL-FC0.148 (0.11)0.378 (0.063)0.066 (0.049)-0.408 (0.166)
M-HDL-L0.133 (0.091)0.491 (0.097)-0.029 (0.086)-0.485 (0.155)
M-HDL-P0.129 (0.097)0.501 (0.097)-0.004 (0.09)-0.472 (0.166)
M-HDL-PL0.162 (0.107)0.519 (0.096)-0.037 (0.087)-0.486 (0.171)
L-HDL-C-0.724 (0.232)0.856 (0.132)0.032 (0.093)0.575 (0.204)
L-HDL-CE-0.761 (0.236)0.899 (0.145)0.004 (0.084)0.61 (0.206)
L-HDL-FC-0.749 (0.174)0.842 (0.102)0.094 (0.05)0.59 (0.148)
L-HDL-L-0.717 (0.217)0.815 (0.12)0.023 (0.089)0.541 (0.184)
L-HDL-P-0.653 (0.191)0.749 (0.104)0.057 (0.049)0.476 (0.155)
L-HDL-PL-0.679 (0.201)0.774 (0.109)0.05 (0.049)0.51 (0.169)
XL-HDL-C-0.639 (0.194)0.692 (0.095)-0.058 (0.086)0.565 (0.196)
XL-HDL-CE-0.576 (0.2)0.667 (0.096)-0.077 (0.086)0.511 (0.206)
XL-HDL-FC-0.734 (0.174)0.674 (0.073)0.094 (0.052)0.609 (0.159)
XL-HDL-L-0.652 (0.168)0.733 (0.097)-0.06 (0.084)0.481 (0.141)
XL-HDL-P-0.52 (0.147)0.691 (0.094)-0.075 (0.084)0.39 (0.135)
XL-HDL-PL-0.652 (0.151)0.687 (0.076)0.079 (0.051)0.466 (0.12)
XL-HDL-TG-0.281 (0.111)0.539 (0.09)-0.152 (0.092)0.165 (0.086)

Q-statistics for multivariable Mendelian randomization

Here we provide the list of modified Cochran's Q-statistics for the multivariable MR analyses (Appendix 3—tables 7 and 8).

Appendix 3—table 7
Modified Cochran’s Q-statistics (p-values) for the multivariable Mendelian randomization analyses (adjusted for HDL-C, LDL-C, and TG).

DF is short for degrees of freedom.

TraitDFHDL-CLDL-CTGSubfraction
VLDL traits
VLDL-D4327640.8 (0)1918.9 (7.9e-186)877.6 (1.4e-32)840.2 (1.6e-28)
XS-VLDL-L4367983.9 (0)1104.9 (1.1e-59)1935.8 (2.2e-187)926 (1.9e-37)
XS-VLDL-P4367927.8 (0)1066.6 (1.1e-54)1814 (4.8e-167)893.6 (9.6e-34)
XS-VLDL-PL4358291.5 (0)968.1 (1.4e-42)2771.5 (0)849.8 (4.3e-29)
XS-VLDL-TG4317549.8 (0)894.4 (1.3e-34)739.5 (1.3e-18)682.5 (1.2e-13)
S-VLDL-C4298598.1 (0)652.6 (1.7e-11)1220.7 (4.6e-77)541.3 (0.00018)
S-VLDL-FC4347861.2 (0)576 (5.4e-06)519.4 (0.003)507.9 (0.0082)
S-VLDL-L4387105.3 (0)626 (8.5e-09)525.2 (0.0026)514.3 (0.0069)
S-VLDL-P4386686.5 (0)616.5 (3.6e-08)515.6 (0.0061)507.3 (0.012)
S-VLDL-PL4377589.1 (0)702.8 (1e-14)591.5 (1.1e-06)555.1 (0.00011)
S-VLDL-TG4377658.7 (0)612.7 (5.3e-08)498.9 (0.021)494.5 (0.03)
M-VLDL-C4329167.8 (0)740.8 (1.3e-18)558.9 (3.5e-05)551.5 (8.3e-05)
M-VLDL-CE4328055.2 (0)705.9 (1.6e-15)556.6 (4.6e-05)539.7 (0.00031)
M-VLDL-FC4368272.8 (0)814.8 (2.7e-25)528.3 (0.0016)519.1 (0.0037)
M-VLDL-L4297109.2 (0)1269.2 (5.5e-84)532.6 (0.00047)515.9 (0.0025)
M-VLDL-P4368260.7 (0)2059.5 (2.1e-208)527.5 (0.0017)516.8 (0.0046)
M-VLDL-PL4356849.2 (0)599.6 (2.6e-07)496.8 (0.021)493.5 (0.027)
M-VLDL-TG4366123.7 (0)9854.8 (0)532.3 (0.0011)521 (0.0031)
L-VLDL-C4358617.2 (0)8966 (0)654.7 (4.3e-11)561.5 (3.9e-05)
L-VLDL-CE4346636.6 (0)11134 (0)581.6 (2.6e-06)539.5 (0.00041)
L-VLDL-FC4317779.6 (0)6691 (0)595.1 (2.5e-07)562.7 (1.9e-05)
L-VLDL-L4348104.9 (0)5191.4 (0)560.3 (3.9e-05)548.6 (0.00015)
L-VLDL-P4352308 (5.1e-252)10360.3 (0)545.4 (0.00024)537.9 (0.00054)
L-VLDL-PL4308155.4 (0)1310.8 (8.6e-90)491.8 (0.021)489.7 (0.024)
L-VLDL-TG4388581.8 (0)4800.1 (0)569.1 (2.3e-05)559.2 (7.5e-05)
XL-VLDL-L4378686.8 (0)8322.2 (0)674.7 (1.9e-12)620.2 (1.7e-08)
XL-VLDL-P4318550.2 (0)2459.4 (2e-280)608.3 (3.6e-08)588.6 (6.3e-07)
XL-VLDL-PL4317478.2 (0)5042.5 (0)613.3 (1.7e-08)591.6 (4.1e-07)
XL-VLDL-TG4338237.3 (0)9628.9 (0)651.8 (4.6e-11)618.3 (1.1e-08)
XXL-VLDL-L4398476.2 (0)10436.4 (0)652.9 (1.3e-10)570.7 (2.2e-05)
XXL-VLDL-P4371291.3 (2.8e-85)9987.4 (0)540.3 (0.00053)529.5 (0.0016)
XXL-VLDL-PL4369631.8 (0)11287.1 (0)641.6 (4.8e-10)595.5 (5.3e-07)
XXL-VLDL-TG4297809.4 (0)9476.4 (0)595.6 (1.7e-07)564 (1.2e-05)
LDL/IDL traits
ApoB4359220.8 (0)550.1 (0.00014)1809.7 (1.2e-166)535.1 (0.00072)
LDL-D4292909.2 (0)3918.8 (0)2706 (0)1426.1 (2.9e-107)
S-LDL-C4318189.7 (0)569.8 (7.8e-06)4880.9 (0)564.1 (1.6e-05)
S-LDL-L4358403.8 (0)574.4 (7.8e-06)3931.2 (0)564.3 (2.7e-05)
S-LDL-P4317371.4 (0)547.1 (0.00012)3144.7 (0)537.9 (0.00034)
M-LDL-C4309723.7 (0)570.9 (5.8e-06)6568.6 (0)562.9 (1.6e-05)
M-LDL-CE4328442.1 (0)558.3 (3.8e-05)5773.6 (0)549.1 (0.00011)
M-LDL-L4308801.7 (0)555.4 (4e-05)5176.1 (0)548.2 (9.5e-05)
M-LDL-P4298798.9 (0)541.6 (0.00018)5049.7 (0)535.2 (0.00035)
M-LDL-PL4367981.7 (0)573.9 (9.6e-06)4304.8 (0)558.9 (6e-05)
L-LDL-C4328865.2 (0)567.7 (1.2e-05)6179.8 (0)567 (1.3e-05)
L-LDL-CE4338464.3 (0)558.7 (4.1e-05)5731.3 (0)555.6 (5.9e-05)
L-LDL-FC4317481.1 (0)580.6 (1.9e-06)6760.8 (0)580.2 (2e-06)
L-LDL-L4338486.8 (0)604.5 (8.9e-08)5755.8 (0)601.8 (1.3e-07)
L-LDL-P4348310.7 (0)592.1 (6.3e-07)5553.3 (0)584.9 (1.7e-06)
L-LDL-PL4358341.4 (0)588.5 (1.2e-06)5327.8 (0)577.4 (5.3e-06)
IDL-C4347873.9 (0)645.5 (1.7e-10)6336 (0)642.1 (2.9e-10)
IDL-FC4328036 (0)729.5 (1.4e-17)6630.5 (0)725.6 (3e-17)
IDL-L4347869.8 (0)694.5 (2.4e-14)5198.3 (0)689 (7e-14)
IDL-P4369660.5 (0)736.7 (9e-18)5002 (0)726.6 (7.1e-17)
IDL-PL4318432.6 (0)680.6 (1.7e-13)5023 (0)677.4 (3e-13)
IDL-TG4367741.2 (0)1077.5 (4.2e-56)1992.9 (4.9e-197)931.6 (4.4e-38)
HDL traits
ApoA1434494.1 (0.024)511.5 (0.006)932.1 (1.8e-38)492 (0.028)
HDL-D438783.5 (6.6e-22)8500 (0)5713.2 (0)860.1 (9.4e-30)
S-HDL-L4383067.3 (0)4414.6 (0)3763.2 (0)882.2 (3.7e-32)
S-HDL-P4382592.4 (1.1e-301)7652.1 (0)3097.3 (0)951.1 (4.9e-40)
S-HDL-TG425896.9 (6.9e-36)641.3 (5.2e-11)540.1 (0.00013)523 (8e-04)
M-HDL-C437957.6 (5.5e-41)10172.4 (0)4875.5 (0)628.3 (4.9e-09)
M-HDL-CE434955.3 (3.2e-41)1383.1 (1.7e-99)4355.4 (0)648.3 (1e-10)
M-HDL-FC432759.4 (2.4e-20)2989.1 (0)3512.2 (0)538.2 (0.00037)
M-HDL-L435914.2 (3e-36)11535.3 (0)2327.7 (1.7e-255)570.3 (1.3e-05)
M-HDL-P434997.6 (2.3e-46)10709.6 (0)1942.9 (3.2e-189)561.3 (3.4e-05)
M-HDL-PL434977.8 (6.3e-44)9439.9 (0)2566 (1.8e-298)581.3 (2.7e-06)
L-HDL-C434580 (3.2e-06)1257.1 (4.4e-81)4502.7 (0)604.3 (1.1e-07)
L-HDL-CE434549 (0.00014)930.2 (3e-38)5517.2 (0)557.2 (5.6e-05)
L-HDL-FC441627.6 (1.2e-08)8415.3 (0)3594 (0)658.4 (7.9e-11)
L-HDL-L434603.6 (1.2e-07)6743.8 (0)5314.7 (0)623.7 (5.7e-09)
L-HDL-P432601.1 (1.2e-07)7769.3 (0)6024.6 (0)633.2 (8.6e-10)
L-HDL-PL434584.5 (1.8e-06)9935.5 (0)3544.3 (0)611.3 (3.8e-08)
XL-HDL-C430732.9 (3.9e-18)10426.6 (0)2077.7 (1.4e-213)686.9 (4e-14)
XL-HDL-CE430771.4 (9.3e-22)8564.4 (0)2457 (2.2e-280)711.4 (3.3e-16)
XL-HDL-FC432761.8 (1.4e-20)11265.2 (0)2549.4 (3.1e-296)770.9 (1.9e-21)
XL-HDL-L429767.6 (1.6e-21)11490.7 (0)2355.7 (1.2e-262)784.6 (3.4e-23)
XL-HDL-P433724.9 (4.6e-17)11372.5 (0)2539.9 (3.9e-294)798.5 (4.8e-24)
XL-HDL-PL443809.7 (7.8e-24)10093.1 (0)5762 (0)895.4 (7.5e-33)
XL-HDL-TG4321849.1 (3.9e-174)2635.9 (6.5e-312)2240.8 (2.9e-241)1267.8 (4.4e-83)
Appendix 3—table 8
Modified Cochran’s Q-statistics (p-values) for the multivariable Mendelian randomization analyses (adjusted for ApoA1, ApoB, and TG).

DF is short for degrees of freedom.

TraitDFApoA1ApoBTGSubfraction
VLDL traits
VLDL-D2971194.1 (9.1e-108)550 (2.4e-17)573.7 (8.2e-20)606.7 (2.1e-23)
XS-VLDL-L2951185.1 (6.7e-107)927 (2e-66)1151.3 (2.2e-101)887.9 (1.1e-60)
XS-VLDL-P2951194.9 (1.7e-108)900 (1.9e-62)895.5 (8.7e-62)826.7 (6.4e-52)
XS-VLDL-PL2961148.5 (1.2e-100)973.9 (3.2e-73)2104.2 (1.4e-269)961.4 (2.5e-71)
XS-VLDL-TG3021263.7 (1.1e-117)757.9 (4.7e-41)1308.1 (4.4e-125)976.5 (4.6e-72)
S-VLDL-C290988.8 (4.4e-77)394 (4.5e-05)459.8 (7.8e-10)402.6 (1.3e-05)
S-VLDL-FC2961092 (1.4e-91)904 (8.6e-63)1238.7 (2.1e-115)1010.4 (8.1e-79)
S-VLDL-L3011107.9 (1.1e-92)412.3 (2.1e-05)420.8 (5.9e-06)384.7 (0.00078)
S-VLDL-P3011116.6 (4.6e-94)424.8 (3.3e-06)401.3 (9.4e-05)380.6 (0.0013)
S-VLDL-PL2991096 (2.3e-91)428.9 (1.2e-06)446 (7.1e-08)432.1 (7.1e-07)
S-VLDL-TG3001152.4 (4.3e-100)908.5 (1.8e-62)1453.4 (1.8e-150)1303.1 (7.1e-125)
M-VLDL-C2981171.2 (1e-103)824 (7.3e-51)1480 (8.9e-156)1212.5 (1.8e-110)
M-VLDL-CE2981185.4 (4.9e-106)564.4 (1.1e-18)468.9 (9.2e-10)431.6 (6.3e-07)
M-VLDL-FC2981190.4 (7.4e-107)899.8 (1.1e-61)415.2 (8.1e-06)398.8 (8.4e-05)
M-VLDL-L2981144.1 (2.4e-99)869.8 (2.4e-57)1381 (1e-138)1237.4 (1.4e-114)
M-VLDL-P2971121.3 (5.7e-96)821.1 (1.1e-50)1250.5 (4.6e-117)1206.7 (8.1e-110)
M-VLDL-PL2981149.9 (2.8e-100)843.2 (1.5e-53)1391.8 (1.5e-140)1226.3 (9.8e-113)
M-VLDL-TG2961187.4 (5.8e-107)717.3 (5.8e-37)366.3 (0.0033)360.6 (0.006)
L-VLDL-C2951196.5 (9.1e-109)820 (5.6e-51)462.5 (1.5e-09)376.9 (0.00088)
L-VLDL-CE3021183.1 (1.8e-104)844.6 (7.4e-53)541.8 (7.2e-16)441.7 (2.6e-07)
L-VLDL-FC2951172.3 (8.2e-105)851.6 (1.9e-55)460.8 (2.1e-09)406.2 (1.8e-05)
L-VLDL-L2951163.6 (2.2e-103)797 (8.8e-48)406.5 (1.7e-05)391.5 (0.00014)
L-VLDL-P2931160.2 (2e-103)809.5 (5.9e-50)420.2 (1.5e-06)407.9 (1e-05)
L-VLDL-PL2961292 (2.6e-124)833.4 (1.3e-52)1216.5 (9.7e-112)1098.9 (1.1e-92)
L-VLDL-TG2941150.8 (1.3e-101)1213.6 (7e-112)1262.6 (5.2e-120)1162.8 (1.5e-103)
XL-VLDL-L2941196 (5.4e-109)829.4 (1.6e-52)442 (4.9e-08)423.6 (1.1e-06)
XL-VLDL-P2941265.9 (1.4e-120)1180.9 (1.6e-106)1202.2 (5.2e-110)982.1 (5.4e-75)
XL-VLDL-PL2961199.1 (6.9e-109)874.2 (1.9e-58)421.2 (2.3e-06)405.6 (2.3e-05)
XL-VLDL-TG2961184.3 (1.8e-106)828.6 (5.9e-52)430.8 (4.9e-07)430.1 (5.5e-07)
XXL-VLDL-L3041119.2 (1.2e-93)1041.9 (1.6e-81)900.9 (2e-60)699.6 (3.2e-33)
XXL-VLDL-P3031148 (1.7e-98)876.4 (4e-57)382.2 (0.0013)366 (0.0076)
XXL-VLDL-PL3031203 (2.1e-107)775.1 (4e-43)438.1 (5.8e-07)376.5 (0.0025)
XXL-VLDL-TG3031183 (3.7e-104)881.8 (6.6e-58)393.7 (0.00034)372.7 (0.0039)
LDL/IDL traits
LDL-C2931198.7 (9.6e-110)938.8 (1.1e-68)1060.2 (2.1e-87)917.6 (1.5e-65)
LDL-D2961325.2 (6.7e-130)747.9 (5.9e-41)879.1 (3.7e-59)1163.5 (4.6e-103)
S-LDL-C2961195.3 (2.9e-108)706 (1.6e-35)1426 (4.1e-147)686.4 (4.8e-33)
S-LDL-L2961054.7 (1.1e-85)608 (1e-23)1519.6 (2.2e-163)586.4 (2.5e-21)
S-LDL-P297852.9 (3.6e-55)438.7 (1.6e-07)954.7 (4.5e-70)440.1 (1.3e-07)
M-LDL-C2961210.9 (8e-111)396.2 (8.6e-05)409 (1.4e-05)398.9 (6e-05)
M-LDL-CE2951204.3 (4.8e-110)350.8 (0.014)361.7 (0.0048)351.3 (0.013)
M-LDL-L2961212 (5.3e-111)370 (0.0022)392.3 (0.00015)371.6 (0.0019)
M-LDL-P2971125.4 (1.2e-96)623.9 (2.3e-25)911.4 (1.3e-63)582.4 (9.6e-21)
M-LDL-PL2991172.5 (1.2e-103)399.3 (9.1e-05)434.9 (4.5e-07)396.2 (0.00014)
L-LDL-C3001174.6 (1.1e-103)325.5 (0.15)325.5 (0.15)325.5 (0.15)
L-LDL-CE2991179.5 (9e-105)769.8 (3e-43)902.5 (7.7e-62)743.8 (8.4e-40)
L-LDL-FC2951161 (5.8e-103)322.4 (0.13)323.2 (0.12)322.3 (0.13)
L-LDL-L3001172.3 (2.6e-103)336.9 (0.07)349.6 (0.026)340.3 (0.055)
L-LDL-P3001185.4 (2e-105)352.1 (0.021)378.4 (0.0014)355.4 (0.015)
L-LDL-PL2961155.2 (9.8e-102)343.2 (0.031)360.1 (0.0063)344.5 (0.027)
IDL-C2961181.7 (4.9e-106)426.5 (9.8e-07)427.6 (8.3e-07)427.7 (8.1e-07)
IDL-FC2981096.5 (9.9e-92)986.9 (1.1e-74)1075.8 (1.9e-88)975.4 (6.1e-73)
IDL-L2961176.1 (4e-105)516.7 (3.3e-14)531 (1.4e-15)521.4 (1.2e-14)
IDL-P2971094.8 (9.5e-92)910.9 (1.5e-63)1103.9 (3.5e-93)890.2 (1.6e-60)
IDL-PL2971107.8 (8.3e-94)798.9 (1.3e-47)931.6 (1.3e-66)785.6 (8.6e-46)
IDL-TG3021060.8 (5.4e-85)1052.1 (1.2e-83)1092.6 (5.6e-90)1118.3 (4.7e-94)
HDL traits
HDL-C298318.7 (0.2)336.3 (0.063)329.1 (0.1)318.6 (0.2)
HDL-D300637.4 (1.9e-26)1156.6 (9.1e-101)2305.2 (1.3e-305)1183.8 (3.5e-105)
S-HDL-L2991597.7 (4.8e-176)1222.5 (8.2e-112)1916.4 (1.5e-233)1057 (3.1e-85)
S-HDL-P2991666.8 (2.5e-188)1249.4 (2.9e-116)2146.5 (3.4e-276)1103.3 (1.6e-92)
S-HDL-TG299899 (2.5e-61)464.9 (2.4e-09)464.5 (2.6e-09)457.6 (9.2e-09)
M-HDL-C2991145.2 (3.2e-99)768.2 (4.9e-43)951.8 (4e-69)786.8 (1.5e-45)
M-HDL-CE2991201.9 (2e-108)1183.9 (1.7e-105)2139.7 (6.4e-275)843.9 (1.9e-53)
M-HDL-FC298881.1 (5.6e-59)1252 (5.5e-117)1989.1 (2.4e-247)660.1 (1.8e-29)
M-HDL-L2991059 (1.5e-85)766.4 (8.7e-43)920.6 (1.7e-64)672.5 (8.6e-31)
M-HDL-P298990.2 (3.5e-75)760.4 (3.4e-42)1027.6 (6.2e-81)613.7 (4.7e-24)
M-HDL-PL295929.5 (8.3e-67)763.9 (2.7e-43)1057.2 (2.3e-86)588.3 (1.1e-21)
L-HDL-C299579.3 (4.1e-20)623.2 (5.7e-25)639.6 (7.3e-27)617.8 (2.3e-24)
L-HDL-CE299612.2 (1e-23)650.7 (3.6e-28)690.4 (5.5e-33)644 (2.2e-27)
L-HDL-FC308581.7 (4.4e-19)857.5 (2.6e-53)1213.3 (1.4e-107)915.8 (1.3e-61)
L-HDL-L299655.9 (8.7e-29)747.7 (2.6e-40)670.7 (1.4e-30)713.2 (7.5e-36)
L-HDL-P298591.3 (1.5e-21)934 (9.9e-67)1269.7 (6.2e-120)956.8 (3.9e-70)
L-HDL-PL299580 (3.4e-20)863.5 (3.3e-56)1262.4 (2.1e-118)891.8 (2.8e-60)
XL-HDL-C298475.3 (2.7e-10)734 (1e-38)976.1 (4.9e-73)554 (1.3e-17)
XL-HDL-CE299472.9 (5.4e-10)736.9 (6.7e-39)1117.4 (9e-95)517.5 (6.5e-14)
XL-HDL-FC295527.8 (2.1e-15)1182.8 (1.6e-106)2169.4 (3.1e-282)677.3 (4.3e-32)
XL-HDL-L298555.2 (9.6e-18)701.2 (1.6e-34)1014 (7.9e-79)775.3 (3.4e-44)
XL-HDL-P300578.9 (6.3e-20)744.5 (1.1e-39)1015.5 (1.6e-78)751.3 (1.4e-40)
XL-HDL-PL306604.9 (7.8e-22)1153.9 (1.4e-98)1899 (1.5e-227)909.3 (3.7e-61)
XL-HDL-TG300702.2 (2.8e-34)779.8 (2.2e-44)1140.8 (3.2e-98)1399.2 (3.7e-141)

Appendix 4

Diagnostic plots and the genetic markers

As mentioned above, RAPS is more robust against invalid instruments than other statistical methods for univariable MR, but it still needs the InSIDE assumption to be approximately satisfied. Zhao et al., 2019b described two diagnostic plots RAPS that checks whether there is clear evidence that the InSIDE assumption is violated. Here, we report these plots for HDL-C and M-HDL-P in different studies (Appendix 4—figures 1 and 2). Notice that a lack of evidence to falsify the InSIDE assumption does not mean that it is true.

S-HDL-P

Appendix 4—figure 1
Diagnostic plots for S-HDL-P (selection: Davis; exposure: Kettunen; outcome: UK Biobank).

M-HDL-P

Appendix 4—figure 2
Diagnostic plots for M-HDL-P (selection: Davis; exposure: Kettunen; outcome: UK Biobank).

Genetic markers for M-HDL-P and S-HDL-P

We can further assess the validity of the InSIDE assumption for M-HDL-P and S-HDL-P but examining the associations of their genetic instruments with the traditional lipid risk factors and other subfraction traits. We meta-analyzed the summary results in the two lipidome GWAS (Davis and Kettunen) and obtained SNPs that are associated with S-HDL-P and M-HDL-P (p-value 5×10-8; the results are LD-clumped). The next two Tables show some information about these genetic markers and their associations with other traits (Appendix 4—table 1 and 2).

Appendix 4—figures 3 and 4 shows how adjusting for LDL-C and TG changes the effects of the selected SNPs for S-HDL-P and M-HDL-P on CAD. The adjusted effect on CAD is obtained by original effect on CAD – 0.45 * effect on LDL-C – 0.25 * effect on TG. After the adjustment, the associations of the genetic variants with CAD generally became closer to the fitted lines that correspond to the estimated effects of S-HDL-P and M-HDL-P.

Appendix 4—table 1
List of SNPs associated with M-HDL-P.
SNPChrGeneS-HDL-PM-HDL-PL-HDL-PXL-HDL-PHDL-CLDL-CTGCAD
rs112080041DOCK7-0.039 **-0.075 ***-0.015-0.002-0.015 **-0.050 ***-0.069 ***-0.012
rs48469131GALNT2-0.000-0.061 ***-0.062 ***-0.023 .-0.055 ***-0.006-0.044 ***-0.025 .
rs21262598LOC157273-0.066 ***-0.082 ***-0.063 **-0.025 .-0.075 ***-0.063 ***-0.016 .-0.004
rs20836378LPL-0.001-0.058 ***-0.092 ***-0.053 **-0.105 ***-0.008-0.108 ***-0.047 **
rs1046801715ALDH1A2/LIPC-0.096 ***-0.060 ***-0.209 ***-0.202 ***-0.118 ***-0.002-0.038 ***-0.013
rs24761616CETP-0.058 ***-0.121 ***-0.198 ***-0.129 ***-0.243 ***-0.055 ***-0.039 ***-0.044 **
rs194397318LIPG-0.022-0.108 ***-0.104 ***-0.078 ***-0.077 ***-0.024 **-0.009-0.016
rs73733719DOCK6-0.047 .-0.087 ***-0.081 **-0.058 *-0.056 ***-0.007-0.011-0.038 .
rs76944919APOE-0.016-0.078 ***-0.071 ***-0.015-0.064 ***-0.214 ***-0.042 ***-0.085 ***
rs767920PCIF1/PLTP-0.188 ***-0.071 ***-0.129 ***-0.152 ***-0.059 ***-0.009-0.051 ***-0.025 .
Appendix 4—table 2
List of SNPs associated with S-HDL-P.
SNPChrGeneS-HDL-PM-HDL-PL-HDL-PXL-HDL-PHDL-CLDL-CTGCAD
rs7800942GCKR-0.074 ***-0.034 *-0.04 **-0.034 *-0.011 .-0.021 **-0.110 ***-0.005
rs109354733ST3GAL6-AS1-0.052 ***-0.014-0.029 .-0.031 *-0.009 .-0.003-0.005-0.007
rs493636311SIK3-0.064 ***-0.046 **-0.019-0.006-0.034 **-0.018 .-0.043 ***-0.022
rs204308515ALDH1A2/LIPC-0.092 ***-0.056 ***-0.202 ***-0.197 ***-0.106 ***-0.003-0.033 ***-0.008
rs180058815ALDH1A2/LIPC-0.106 ***-0.050 **-0.215 ***-0.212 ***-0.114 ***-0.002-0.044 ***-0.015
rs28971416CETP-0.077 ***-0.122 ***-0.162 ***-0.102 ***-0.214 ***-0.036 ***-0.035 ***-0.012
rs606590420PLTP-0.171 ***-0.060 ***-0.127 ***-0.149 ***-0.052 ***-0.008-0.040 ***-0.022 .
Appendix 4—figure 3
Scatter-plots for S-HDL-P with the effects on CAD adjusted for LDL-C and TG.

Red lines correspond the fitted effects of S-HDL-P in multivariable MR.

Appendix 4—figure 4
Scatter-plots for M-HDL-P with the effects on CAD adjusted for LDL-C and TG.

Red lines correspond the fitted effects of M-HDL-P in multivariable MR.

Gene expression

Here we provide evidence of variant-gene associations from Quantatitive Trait Locus (QTL) analyses in the GTEx project (Appendix 4—table 3).

Appendix 4—table 3
Tissue-specific gene expressions associated with the 4 discovered genetic markers in the GTEx project.
SNP.IdTypeGene.SymbolVariant.Idp valueEffectTissue
rs838880eQTLSCARB1chr12_124777047_C_T_b381.5E-08-0.20Cells - Cultured fibroblasts
rs838880sQTLSCARB1chr12_124777047_C_T_b384.1E-06-0.34Testis
rs737337sQTLDOCK6chr19_11236817_T_C_b383.8E-430.99Artery - Tibial
rs737337sQTLDOCK6chr19_11236817_T_C_b386.4E-350.93Adipose - Subcutaneous
rs737337sQTLDOCK6chr19_11236817_T_C_b386.4E-350.93Adipose - Subcutaneous
rs737337sQTLDOCK6chr19_11236817_T_C_b381.6E-270.95Esophagus - Muscularis
rs737337sQTLDOCK6chr19_11236817_T_C_b383.2E-201.10Colon - Sigmoid
rs737337sQTLDOCK6chr19_11236817_T_C_b381.1E-170.93Esophagus - Gastroesophageal Junction
rs737337sQTLDOCK6chr19_11236817_T_C_b381.8E-090.81Artery - Coronary
rs737337sQTLDOCK6chr19_11236817_T_C_b381.2E-07-0.49Thyroid
rs737337sQTLKANK2chr19_11236817_T_C_b384.4E-070.43Artery - Tibial
rs737337sQTLKANK2chr19_11236817_T_C_b383.5E-060.55Heart - Left Ventricle
rs2943641eQTLIRS1chr2_226229029_T_C_b381.4E-16-0.30Adipose - Subcutaneous
rs2943641eQTLIRS1chr2_226229029_T_C_b386.1E-12-0.23Adipose - Visceral (Omentum)
rs2943641eQTLRP11-395N3.2chr2_226229029_T_C_b383.5E-09-0.23Adipose - Subcutaneous
rs2943641eQTLRP11-395N3.1chr2_226229029_T_C_b382.1E-07-0.23Adipose - Subcutaneous
rs2943641eQTLRP11-395N3.2chr2_226229029_T_C_b382.3E-06-0.19Adipose - Visceral (Omentum)
rs6065904eQTLPLTPchr20_45906012_G_A_b384.4E-22-0.27Muscle - Skeletal
rs6065904eQTLPLTPchr20_45906012_G_A_b381.6E-16-0.27Adipose - Subcutaneous
rs6065904eQTLPLTPchr20_45906012_G_A_b381.2E-15-0.28Adipose - Visceral (Omentum)
rs6065904eQTLPLTPchr20_45906012_G_A_b383.2E-15-0.42Heart - Atrial Appendage
rs6065904eQTLPLTPchr20_45906012_G_A_b387.2E-14-0.25Artery - Tibial
rs6065904eQTLPLTPchr20_45906012_G_A_b381.8E-12-0.27Nerve - Tibial
rs6065904eQTLPLTPchr20_45906012_G_A_b387.3E-12-0.26Esophagus - Muscularis
rs6065904eQTLPLTPchr20_45906012_G_A_b382.0E-11-0.29Colon - Transverse
rs6065904eQTLPLTPchr20_45906012_G_A_b384.1E-11-0.32Colon - Sigmoid
rs6065904eQTLPLTPchr20_45906012_G_A_b381.2E-09-0.26Artery - Aorta
rs6065904eQTLPLTPchr20_45906012_G_A_b384.2E-09-0.29Heart - Left Ventricle
rs6065904eQTLPLTPchr20_45906012_G_A_b385.0E-09-0.22Thyroid
rs6065904eQTLPLTPchr20_45906012_G_A_b381.7E-08-0.29Stomach
rs6065904eQTLPLTPchr20_45906012_G_A_b384.3E-08-0.24Lung
rs6065904eQTLNEURL2chr20_45906012_G_A_b386.6E-08-0.26Adipose - Subcutaneous
rs6065904eQTLPLTPchr20_45906012_G_A_b386.8E-08-0.33Liver
rs6065904eQTLCTSAchr20_45906012_G_A_b384.0E-07-0.14Nerve - Tibial
rs6065904eQTLPLTPchr20_45906012_G_A_b385.3E-07-0.37Spleen
rs6065904eQTLNEURL2chr20_45906012_G_A_b385.6E-07-0.26Adipose - Visceral (Omentum)
rs6065904eQTLPLTPchr20_45906012_G_A_b388.9E-07-0.46Small Intestine - Terminal Ileum
rs6065904eQTLRP3-337O18.9chr20_45906012_G_A_b381.8E-06-0.22Adipose - Subcutaneous
rs6065904eQTLWFDC3chr20_45906012_G_A_b382.9E-06-0.31Nerve - Tibial
rs6065904eQTLDNTTIP1chr20_45906012_G_A_b383.1E-06-0.17Artery - Tibial
rs6065904eQTLWFDC3chr20_45906012_G_A_b384.5E-06-0.27Skin - Sun Exposed (Lower leg)
rs6065904eQTLSNX21chr20_45906012_G_A_b384.8E-06-0.15Esophagus - Muscularis
rs6065904eQTLWFDC3chr20_45906012_G_A_b388.9E-06-0.27Skin - Not Sun Exposed (Suprapubic)
rs6065904eQTLDNTTIP1chr20_45906012_G_A_b381.0E-05-0.14Nerve - Tibial
rs6065904eQTLPLTPchr20_45906012_G_A_b381.1E-05-0.27Prostate
rs6065904eQTLPLTPchr20_45906012_G_A_b381.3E-05-0.26Pituitary
rs6065904eQTLPLTPchr20_45906012_G_A_b381.4E-05-0.21Esophagus - Gastroesophageal Junction
rs6065904eQTLSNX21chr20_45906012_G_A_b381.5E-05-0.16Esophagus - Mucosa
rs6065904eQTLSNX21chr20_45906012_G_A_b381.7E-05-0.23Colon - Sigmoid
rs6065904eQTLSNX21chr20_45906012_G_A_b381.7E-05-0.17Thyroid
rs6065904eQTLPLTPchr20_45906012_G_A_b382.6E-05-0.21Breast - Mammary Tissue
rs6065904eQTLWFDC3chr20_45906012_G_A_b382.9E-05-0.23Artery - Tibial
rs6065904eQTLNEURL2chr20_45906012_G_A_b383.2E-05-0.21Thyroid
rs6065904eQTLPLTPchr20_45906012_G_A_b383.7E-05-0.17Testis
rs6065904eQTLCTSAchr20_45906012_G_A_b384.4E-05-0.11Skin - Not Sun Exposed (Suprapubic)
rs6065904eQTLWFDC3chr20_45906012_G_A_b385.8E-05-0.23Muscle - Skeletal
rs6065904eQTLNEURL2chr20_45906012_G_A_b388.2E-05-0.27Heart - Atrial Appendage
rs6065904eQTLSNX21chr20_45906012_G_A_b388.4E-05-0.17Artery - Aorta
rs6065904eQTLNEURL2chr20_45906012_G_A_b389.5E-05-0.24Artery - Aorta
rs6065904eQTLWFDC3chr20_45906012_G_A_b389.5E-05-0.31Artery - Aorta
rs6065904eQTLRP3-337O18.9chr20_45906012_G_A_b389.5E-05-0.29Heart - Atrial Appendage
rs6065904eQTLPLTPchr20_45906012_G_A_b381.2E-04-0.15Skin - Sun Exposed (Lower leg)
rs6065904eQTLWFDC13chr20_45906012_G_A_b381.5E-040.28Esophagus - Muscularis
rs6065904eQTLDNTTIP1chr20_45906012_G_A_b382.1E-04-0.12Cells - Cultured fibroblasts
rs6065904sQTLZNF335chr20_45906012_G_A_b383.3E-11-0.65Testis
rs6065904sQTLACOT8chr20_45906012_G_A_b381.3E-090.58Heart - Left Ventricle
rs6065904sQTLPLTPchr20_45906012_G_A_b384.5E-08-0.32Whole Blood
rs6065904sQTLPLTPchr20_45906012_G_A_b384.8E-080.53Spleen
rs6065904sQTLACOT8chr20_45906012_G_A_b381.3E-070.42Esophagus - Mucosa
rs6065904sQTLACOT8chr20_45906012_G_A_b382.6E-070.49Heart - Atrial Appendage
rs6065904sQTLCTSAchr20_45906012_G_A_b381.0E-06-0.41Artery - Aorta
rs6065904sQTLACOT8chr20_45906012_G_A_b381.2E-060.33Nerve - Tibial
rs6065904sQTLACOT8chr20_45906012_G_A_b381.2E-060.67Brain - Spinal cord (cervical c-1)
rs6065904sQTLTNNC2chr20_45906012_G_A_b382.1E-060.54Brain - Cerebellum
rs6065904sQTLACOT8chr20_45906012_G_A_b382.1E-060.54Brain - Cerebellum
rs6065904sQTLWFDC3chr20_45906012_G_A_b385.5E-060.23Skin - Sun Exposed (Lower leg)
rs6065904sQTLWFDC3chr20_45906012_G_A_b389.4E-06-0.28Skin - Not Sun Exposed (Suprapubic)

Data availability

GWAS data used in the data are publicly available. Details can be found in Table 1.

References

    1. Nikpay M
    2. Goel A
    3. Won HH
    4. Hall LM
    5. Willenborg C
    6. Kanoni S
    7. Saleheen D
    8. Kyriakou T
    9. Nelson CP
    10. Hopewell JC
    11. Webb TR
    12. Zeng L
    13. Dehghan A
    14. Alver M
    15. Armasu SM
    16. Auro K
    17. Bjonnes A
    18. Chasman DI
    19. Chen S
    20. Ford I
    21. Franceschini N
    22. Gieger C
    23. Grace C
    24. Gustafsson S
    25. Huang J
    26. Hwang SJ
    27. Kim YK
    28. Kleber ME
    29. Lau KW
    30. Lu X
    31. Lu Y
    32. Lyytikäinen LP
    33. Mihailov E
    34. Morrison AC
    35. Pervjakova N
    36. Qu L
    37. Rose LM
    38. Salfati E
    39. Saxena R
    40. Scholz M
    41. Smith AV
    42. Tikkanen E
    43. Uitterlinden A
    44. Yang X
    45. Zhang W
    46. Zhao W
    47. de Andrade M
    48. de Vries PS
    49. van Zuydam NR
    50. Anand SS
    51. Bertram L
    52. Beutner F
    53. Dedoussis G
    54. Frossard P
    55. Gauguier D
    56. Goodall AH
    57. Gottesman O
    58. Haber M
    59. Han BG
    60. Huang J
    61. Jalilzadeh S
    62. Kessler T
    63. König IR
    64. Lannfelt L
    65. Lieb W
    66. Lind L
    67. Lindgren CM
    68. Lokki ML
    69. Magnusson PK
    70. Mallick NH
    71. Mehra N
    72. Meitinger T
    73. Memon FU
    74. Morris AP
    75. Nieminen MS
    76. Pedersen NL
    77. Peters A
    78. Rallidis LS
    79. Rasheed A
    80. Samuel M
    81. Shah SH
    82. Sinisalo J
    83. Stirrups KE
    84. Trompet S
    85. Wang L
    86. Zaman KS
    87. Ardissino D
    88. Boerwinkle E
    89. Borecki IB
    90. Bottinger EP
    91. Buring JE
    92. Chambers JC
    93. Collins R
    94. Cupples LA
    95. Danesh J
    96. Demuth I
    97. Elosua R
    98. Epstein SE
    99. Esko T
    100. Feitosa MF
    101. Franco OH
    102. Franzosi MG
    103. Granger CB
    104. Gu D
    105. Gudnason V
    106. Hall AS
    107. Hamsten A
    108. Harris TB
    109. Hazen SL
    110. Hengstenberg C
    111. Hofman A
    112. Ingelsson E
    113. Iribarren C
    114. Jukema JW
    115. Karhunen PJ
    116. Kim BJ
    117. Kooner JS
    118. Kullo IJ
    119. Lehtimäki T
    120. Loos RJF
    121. Melander O
    122. Metspalu A
    123. März W
    124. Palmer CN
    125. Perola M
    126. Quertermous T
    127. Rader DJ
    128. Ridker PM
    129. Ripatti S
    130. Roberts R
    131. Salomaa V
    132. Sanghera DK
    133. Schwartz SM
    134. Seedorf U
    135. Stewart AF
    136. Stott DJ
    137. Thiery J
    138. Zalloua PA
    139. O'Donnell CJ
    140. Reilly MP
    141. Assimes TL
    142. Thompson JR
    143. Erdmann J
    144. Clarke R
    145. Watkins H
    146. Kathiresan S
    147. McPherson R
    148. Deloukas P
    149. Schunkert H
    150. Samani NJ
    151. Farrall M
    (2015) A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease
    Nature Genetics 47:1121.
    https://doi.org/10.1038/ng.3396
    1. Voight BF
    2. Peloso GM
    3. Orho-Melander M
    4. Frikke-Schmidt R
    5. Barbalic M
    6. Jensen MK
    7. Hindy G
    8. Hólm H
    9. Ding EL
    10. Johnson T
    11. Schunkert H
    12. Samani NJ
    13. Clarke R
    14. Hopewell JC
    15. Thompson JF
    16. Li M
    17. Thorleifsson G
    18. Newton-Cheh C
    19. Musunuru K
    20. Pirruccello JP
    21. Saleheen D
    22. Chen L
    23. Stewart A
    24. Schillert A
    25. Thorsteinsdottir U
    26. Thorgeirsson G
    27. Anand S
    28. Engert JC
    29. Morgan T
    30. Spertus J
    31. Stoll M
    32. Berger K
    33. Martinelli N
    34. Girelli D
    35. McKeown PP
    36. Patterson CC
    37. Epstein SE
    38. Devaney J
    39. Burnett MS
    40. Mooser V
    41. Ripatti S
    42. Surakka I
    43. Nieminen MS
    44. Sinisalo J
    45. Lokki ML
    46. Perola M
    47. Havulinna A
    48. de Faire U
    49. Gigante B
    50. Ingelsson E
    51. Zeller T
    52. Wild P
    53. de Bakker PI
    54. Klungel OH
    55. Maitland-van der Zee AH
    56. Peters BJ
    57. de Boer A
    58. Grobbee DE
    59. Kamphuisen PW
    60. Deneer VH
    61. Elbers CC
    62. Onland-Moret NC
    63. Hofker MH
    64. Wijmenga C
    65. Verschuren WM
    66. Boer JM
    67. van der Schouw YT
    68. Rasheed A
    69. Frossard P
    70. Demissie S
    71. Willer C
    72. Do R
    73. Ordovas JM
    74. Abecasis GR
    75. Boehnke M
    76. Mohlke KL
    77. Daly MJ
    78. Guiducci C
    79. Burtt NP
    80. Surti A
    81. Gonzalez E
    82. Purcell S
    83. Gabriel S
    84. Marrugat J
    85. Peden J
    86. Erdmann J
    87. Diemert P
    88. Willenborg C
    89. König IR
    90. Fischer M
    91. Hengstenberg C
    92. Ziegler A
    93. Buysschaert I
    94. Lambrechts D
    95. Van de Werf F
    96. Fox KA
    97. El Mokhtari NE
    98. Rubin D
    99. Schrezenmeir J
    100. Schreiber S
    101. Schäfer A
    102. Danesh J
    103. Blankenberg S
    104. Roberts R
    105. McPherson R
    106. Watkins H
    107. Hall AS
    108. Overvad K
    109. Rimm E
    110. Boerwinkle E
    111. Tybjaerg-Hansen A
    112. Cupples LA
    113. Reilly MP
    114. Melander O
    115. Mannucci PM
    116. Ardissino D
    117. Siscovick D
    118. Elosua R
    119. Stefansson K
    120. O'Donnell CJ
    121. Salomaa V
    122. Rader DJ
    123. Peltonen L
    124. Schwartz SM
    125. Altshuler D
    126. Kathiresan S
    (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
    The Lancet 380:572–580.
    https://doi.org/10.1016/S0140-6736(12)60312-2
    1. Willer CJ
    2. Schmidt EM
    3. Sengupta S
    4. Peloso GM
    5. Gustafsson S
    6. Kanoni S
    7. Ganna A
    8. Chen J
    9. Buchkovich ML
    10. Mora S
    11. Beckmann JS
    12. Bragg-Gresham JL
    13. Chang HY
    14. Demirkan A
    15. Den Hertog HM
    16. Do R
    17. Donnelly LA
    18. Ehret GB
    19. Esko T
    20. Feitosa MF
    21. Ferreira T
    22. Fischer K
    23. Fontanillas P
    24. Fraser RM
    25. Freitag DF
    26. Gurdasani D
    27. Heikkilä K
    28. Hyppönen E
    29. Isaacs A
    30. Jackson AU
    31. Johansson Å
    32. Johnson T
    33. Kaakinen M
    34. Kettunen J
    35. Kleber ME
    36. Li X
    37. Luan J
    38. Lyytikäinen LP
    39. Magnusson PKE
    40. Mangino M
    41. Mihailov E
    42. Montasser ME
    43. Müller-Nurasyid M
    44. Nolte IM
    45. O'Connell JR
    46. Palmer CD
    47. Perola M
    48. Petersen AK
    49. Sanna S
    50. Saxena R
    51. Service SK
    52. Shah S
    53. Shungin D
    54. Sidore C
    55. Song C
    56. Strawbridge RJ
    57. Surakka I
    58. Tanaka T
    59. Teslovich TM
    60. Thorleifsson G
    61. Van den Herik EG
    62. Voight BF
    63. Volcik KA
    64. Waite LL
    65. Wong A
    66. Wu Y
    67. Zhang W
    68. Absher D
    69. Asiki G
    70. Barroso I
    71. Been LF
    72. Bolton JL
    73. Bonnycastle LL
    74. Brambilla P
    75. Burnett MS
    76. Cesana G
    77. Dimitriou M
    78. Doney ASF
    79. Döring A
    80. Elliott P
    81. Epstein SE
    82. Ingi Eyjolfsson G
    83. Gigante B
    84. Goodarzi MO
    85. Grallert H
    86. Gravito ML
    87. Groves CJ
    88. Hallmans G
    89. Hartikainen AL
    90. Hayward C
    91. Hernandez D
    92. Hicks AA
    93. Holm H
    94. Hung YJ
    95. Illig T
    96. Jones MR
    97. Kaleebu P
    98. Kastelein JJP
    99. Khaw KT
    100. Kim E
    101. Klopp N
    102. Komulainen P
    103. Kumari M
    104. Langenberg C
    105. Lehtimäki T
    106. Lin SY
    107. Lindström J
    108. Loos RJF
    109. Mach F
    110. McArdle WL
    111. Meisinger C
    112. Mitchell BD
    113. Müller G
    114. Nagaraja R
    115. Narisu N
    116. Nieminen TVM
    117. Nsubuga RN
    118. Olafsson I
    119. Ong KK
    120. Palotie A
    121. Papamarkou T
    122. Pomilla C
    123. Pouta A
    124. Rader DJ
    125. Reilly MP
    126. Ridker PM
    127. Rivadeneira F
    128. Rudan I
    129. Ruokonen A
    130. Samani N
    131. Scharnagl H
    132. Seeley J
    133. Silander K
    134. Stančáková A
    135. Stirrups K
    136. Swift AJ
    137. Tiret L
    138. Uitterlinden AG
    139. van Pelt LJ
    140. Vedantam S
    141. Wainwright N
    142. Wijmenga C
    143. Wild SH
    144. Willemsen G
    145. Wilsgaard T
    146. Wilson JF
    147. Young EH
    148. Zhao JH
    149. Adair LS
    150. Arveiler D
    151. Assimes TL
    152. Bandinelli S
    153. Bennett F
    154. Bochud M
    155. Boehm BO
    156. Boomsma DI
    157. Borecki IB
    158. Bornstein SR
    159. Bovet P
    160. Burnier M
    161. Campbell H
    162. Chakravarti A
    163. Chambers JC
    164. Chen YI
    165. Collins FS
    166. Cooper RS
    167. Danesh J
    168. Dedoussis G
    169. de Faire U
    170. Feranil AB
    171. Ferrières J
    172. Ferrucci L
    173. Freimer NB
    174. Gieger C
    175. Groop LC
    176. Gudnason V
    177. Gyllensten U
    178. Hamsten A
    179. Harris TB
    180. Hingorani A
    181. Hirschhorn JN
    182. Hofman A
    183. Hovingh GK
    184. Hsiung CA
    185. Humphries SE
    186. Hunt SC
    187. Hveem K
    188. Iribarren C
    189. Järvelin MR
    190. Jula A
    191. Kähönen M
    192. Kaprio J
    193. Kesäniemi A
    194. Kivimaki M
    195. Kooner JS
    196. Koudstaal PJ
    197. Krauss RM
    198. Kuh D
    199. Kuusisto J
    200. Kyvik KO
    201. Laakso M
    202. Lakka TA
    203. Lind L
    204. Lindgren CM
    205. Martin NG
    206. März W
    207. McCarthy MI
    208. McKenzie CA
    209. Meneton P
    210. Metspalu A
    211. Moilanen L
    212. Morris AD
    213. Munroe PB
    214. Njølstad I
    215. Pedersen NL
    216. Power C
    217. Pramstaller PP
    218. Price JF
    219. Psaty BM
    220. Quertermous T
    221. Rauramaa R
    222. Saleheen D
    223. Salomaa V
    224. Sanghera DK
    225. Saramies J
    226. Schwarz PEH
    227. Sheu WH
    228. Shuldiner AR
    229. Siegbahn A
    230. Spector TD
    231. Stefansson K
    232. Strachan DP
    233. Tayo BO
    234. Tremoli E
    235. Tuomilehto J
    236. Uusitupa M
    237. van Duijn CM
    238. Vollenweider P
    239. Wallentin L
    240. Wareham NJ
    241. Whitfield JB
    242. Wolffenbuttel BHR
    243. Ordovas JM
    244. Boerwinkle E
    245. Palmer CNA
    246. Thorsteinsdottir U
    247. Chasman DI
    248. Rotter JI
    249. Franks PW
    250. Ripatti S
    251. Cupples LA
    252. Sandhu MS
    253. Rich SS
    254. Boehnke M
    255. Deloukas P
    256. Kathiresan S
    257. Mohlke KL
    258. Ingelsson E
    259. Abecasis GR
    260. Global Lipids Genetics Consortium
    (2013) Discovery and refinement of loci associated with lipid levels
    Nature Genetics 45:1274.
    https://doi.org/10.1038/ng.2797

Decision letter

  1. Edward D Janus
    Reviewing Editor; University of Melbourne, Australia
  2. Matthias Barton
    Senior Editor; University of Zurich, Switzerland
  3. David Sullivan
    Reviewer
  4. Jie Zheng
    Reviewer; University of Bristol, United Kingdom

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Acceptance summary:

This paper is a welcome extension of the use of Mendelian Randomization in the evaluation of the role of lipoprotein sub-fractions. It is necessarily complex. The confirmation of the atherogenicity of summary estimates of LDL and VLDL is useful as are new insights into the protective role of HDL sub-fractions.

Decision letter after peer review:

Thank you for submitting your article "A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease" for consideration by eLife. Your article has been reviewed by 4 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Matthias Barton as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: David Sullivan (Reviewer #1); Jie Zheng (Reviewer #4).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but if as described below additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is "in revision at eLife". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary:

Zhao et al. apply an array of MR approaches to attempt to disentangle the contributions of different lipoprotein subclasses to coronary artery disease risk. They also try to answer the debate about "what matters the most", the lipid content of the lipoproteins or the number of particles. They conclude that LDL and VLDL sub-fractions have a universally adverse effect on coronary artery disease and myocardial infarction and that small dense LDL is not more atherogenic. HDL sub-fractions are heterogeneous in their effects with medium sized particle being protective and this supports the HDL function hypothesis.

Essential revisions:

There are aspects of the study design that could be improved and discussed more critically because some of the interpretations are not straightforward. Overall comprehension of the paper would be greatly aided by a more detailed consideration of the relationship between the different lipoprotein classes and subclasses, and a clear explanation of parameters of interest.

Essential are a substantially clearer description of the results (requiring major revision of the manuscript), stronger justification of the statistical approach taken and explanation as to why results for some fractions are not presented. A preferred alternative is to present results for all fractions even if only in supplementary tables.

1. In the abstract and text please modify the use of the terms positive and negative effects. Clinicians interpret positive as meaning beneficial when referring to outcomes eg in RCTs and negative as ineffective or harmful. In this paper positive and negative appropriately refer to the directions of the associations found. To remove any potential ambiguity for readers please consider using positive (harmful) and negative (protective) or a similar rewording of your choice when these terms first appear in the abstract and main text.

2. The analyses presented are laudably thorough in detail, using different combinations of datasets in which variants to be used for analysis are identified in different summary statistics from those used for the MR itself. There does not appear to have been a prior hypothesis to this work. Rather, it seems that all possible analyses have been conducted and the results then mined for potentially noteworthy findings. While such analyses are useful in themselves the conclusions drawn are suspect and, in places, contradicted by other parts of the authors' own results. The main results also rest on a new method which has yet to be established as valid or workable in this context – GRAPPLE has only recently been described in a bioRXiV preprint, applied to traits with well over 100 independent genome-wide associations, and separate publication resting almost entirely on results using it, applied to traits with much less well-powered GWAS, is premature at best.

3. Genetic correlation analysis – The genetic correlation analysis seems to be stand alone to other MR analyses. The listed motivation of this analysis is to check whether the MR findings are independent to each other. However, it is clear that all these lipid sub-fractions are highly correlated to each other (genetically and observationally), especially for VLDL and LDL sub-fractions. So the rationale of linking TG with VLDL was not tested (although biologically VLDL is the main particle carrying TG in fasting). Even in a clustering point of view, it is hard to split the lipid sub-fraction into three groups: VLDL-TG, IDL/LDL-LDL-C and HDL-HDL-C.

Also some of the rg estimates are missing in Figure 1, e.g. TG is related to the key findings but not included in this genetic correlation analysis.

Also, in a method point of view there are some new genetic correlation methods coming out recently https://www.nature.com/articles/s41588-020-0653-y, which could be considered.

4. Instrument selection – From a practical point of view, It is tricky to jointly model TG with VLDL subtypes characteristics in MVMR because it is unlikely that one would have genetic instruments that strongly predict each exposure once adjusting for the others. Therefore, weak instrument bias is probably an issue here. This is worrying as weak instrument bias in MVMR is not necessarily conservative. At a minimum please provide the conditional F statistics for the MVMR model for each exposure.

5. The authors present a large amount of results for (unadjusted) univariate MR. Given the known highly pleiotropic nature of variants affecting lipoproteins and their sub-fractions, presentation of these in the main figure adds little and obscures the main results of potential note. The full results could be presented as supplementary data, but the main figures should be restricted to multivariable MR.

6. Independent effects of lipid sub-fractions? multivariable MR (MVMR)

One of the key issue for lipids sub-fractions (and other metabolites such as fatty acids) is all the sub-fractions are highly correlated to each other. It is almost impossible to include all of the sub-fractions in the same MVMR model. Some methods considering reduce the dimensionality to solve this issue. In this study, the author used a different approach, which split the lipid sub-fractions into three classes, HDL, LDL and TG related. In this way, the MVMR could be conducted with limited number of variables. However, a lot of SNPs are associated with two or more lipid phenotypes, e.g. the CETP example the author provided in Table 3, the SNP is associated with HDL-C, LDL-C and TG. Even in a MVMR model controlling for LDL-C and TG, it is still hard to prove that the highlighted M-HDL-P finding showed an independent effect on CAD.

Also, more and more studies considered APOB and APOA1 in the MVMR model (e.g. https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1003062), so at least worth including APOB/APOA1 in the MVMR model.

7. VLDL MR results – For VLDL results, some of them showed negative effects (CIs did not cross OR=1) in the MVMR model but positive effect in UVMR model, which seems complex and did not fit with the simple interpretation that "VLDL subfraction traits had uniformly positive effect on coronary artery disease" mentioned in the abstract. Can the authors discuss this in a bit more details and try to find the reason?

8. There are multiple lipidomics measures which are available from the NMR platform, but which are not analyzed, including critical ones such as M-HDL-TG. This needs explanation and/or rectification, since complete data would address multiple points. For instance, the authors dismiss the positive association of S-HDL-TG as being confounded by correlation with VLDL fractions, despite VLDL fractions not having any independent positive effect on CAD in the multivariable analysis. Results for M-HDL-TG would be very informative, and would avoid the possibility that erroneous conclusions are drawn simply because contrary data is missing.

9. It is unclear that it is appropriate to adjust for overall LDL-C when analyzing HDL sub-fractions. Attempting to analyze sub-fractions of one class alongside an aggregate measure of another (which is correlated with aggregate measures of the first) seems suspect and at the very least requires detailed and careful justification.

10. The introduction anticipates the resolution of conflicting findings in relation to LDL size. This is dealt with in discussion, but it needs to be be highlighted beforehand in results. Since levels of different sized LDL and VLDL particles are strongly correlated, a statement that different sizes are not differently atherogenic is not supported by the data. To draw this conclusions would require multivariable MR in which the different size classes were adjusted for each other. In fact, the statement is directly contradicted by the clear associations of VLDL and (particularly) LDL diameter with CAD.

11. Similarly the statement that medium and small HDL particles are protective is contradicted by the fact that HDL particle diameter shows no association at all with CAD risk.

12. Selection of lipid sub-fractions – 82 lipid sub-fractions were selected but it is not directly clear why these fractions (but not others) were selected. It will be helpful to have a DAG to explain the inclusion and exclusion criteria. There is an even more fundamental question: Does this data justify a re-classification of NMR lipoprotein subclasses? Most people would agree that 82 is a few too many. Can the authors nominate a rational condensation of NMR lipoprotein sub-fraction data into a handful of independently predictive parameters with putative mechanisms? Ideally, these would be targets for therapy and indicators of response.

13. HDL MR results – For S-HDL-TG, this is a very complex case and it is doubtful if the current setting can distinguish its effect driven by HDL from its effect driven by TG. I personally think its strong genetic correlation with VLDL (Figure 1) implies that the effect of S-HDL-TG on CAD is driven by TG. However, the MVMR adjusted TG showed similar effect estimate, which suggest the effect is independent to TG (as mentioned about, the reviewer is not sure the MVMR model can prove independent effect). The authors may need to consider integrating some biological information of each instruments been used here to dig into the button of this case study. For example, whether each of instrument colocalized with the expression level of the cis gene in multiple tissues. For the colocalized genes, are they related to HDL pathway or TG pathway etc. This could be very complex so the reviewer suggests to explain the results with caution.

For M-HDL-P, it showed some correlations with HDL-C and APOA1, so hard to say it is not correlated with HDL-C at all.

14. The identification of a leading role for mid-sized HDL particles presents a tantalizing opportunity to link the latter finding with recent NMR studies of cholesterol efflux, but this is not pursued. It would be worth flagging this opportunity at least in the discussion if you cannot easily address it. How do the results (M-HDL-P etc) relate to NMR assessments of cholesterol efflux capacity (eg Direct estimation of HDL-mediated cholesterol efflux capacity from serum. Sanna Kuusisto, Michael V. Holmes, Pauli Ohukainen, Antti J. Kangas, Mari Karsikas, Mika Tiainen, Markus Perola, Veikko Salomaa, Johannes Kettunen, Mika Ala-Korpela doi: https://doi.org/10.1101/396929, now published in Clinical Chemistry doi: 10.1373/clinchem.2018.299222).

15. The multiple versions of the analysis using different combinations of datasets do provide worthwhile technical replication. However, these do not provide wider replication of the findings since any shortcomings in one analysis (e.g. in failing to fully address pleiotropy) will inevitably be present in another.

16. A failure to find evidence against the INSIDE assumption, on the basis of only a small number of SNPs, is a very weak basis for making a claim that there is not horizontal pleiotropy affecting LDL-C or TG. The arguments made by the authors on this point are very weak.

17. The issue of horizontal pleiotropy, especially as it applies to m-HDL-P in relation to the inSIDE assumptions for TG and LDL-C, is justified in discussion and acknowledged in limitations, but it is very difficult follow. For example, from table 3, TG is strongly associated with all traits apart from LOC157273, LIPG and DOCK6. Accordingly, the simple clinician is tempted to regard m-HDL-P as a surrogate for TG. Perhaps there needs to be greater clarity concerning the concepts of genetic correlation and "weak instrument bias".

18. Discussion – "Our results for the HDL sub-fractions support the conclusion that HDL-C is not the causally relevant biomarker." The MR estimate of S-HDL-TG, M-HLD-C and M-HDL-L showed the complexity of HDL-C on CAD. So this claim seems against the main finding of the manuscript.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "A Mendelian randomization study of the role of lipoprotein sub-fractions in coronary artery disease" for further consideration by eLife. Your revised article has been evaluated by a Reviewing Editor and a Senior Editor.

The manuscript has been improved but there are some remaining issues noted by the reviewers that need to be addressed, as outlined below:

You have made substantial efforts to restructure the manuscript (e.g. using genetic correlation as a filtering step in the new version), highlighted the key findings of HDL particle size on CAD as well as identified four potential causal genes linking HDL particle size with CAD. We are in general more convinced that the new findings from this study will bring good value for the existing argument for effect of HDL on CAD.

1. The statistical superiority of HDL over TG is largely a reflection of the greater intra-individual biological variability of the LATTER. This is really the crux of our concern. It seems likely that TG and HDL size represent a gene/environment interaction with a very large environmental component. We are concerned that environmental factors could distort a Mendelian Randomization perspective of this analysis in a way in which the statistics used are valid, but conclusions are not generalizable. This can be addressed in the discussion maybe as a limitation.

2. A sentence in the abstract which summarizes the key findings and potential value of the study would be helpful.

3. Methods, genetic correlation. The authors claim that genetic correlation "is generally different from epidemiological correlation that is estimated from cross-sectional data." By concept, the genetic correlation and phenotypic correlation are different. But in the metabolites case, they have very similar estimates! So please refine this statement to make sure you are just talking about the concept.

4. A very brief introduction about genome-wide MR will be helpful. e.g. did you do LD pruning or any other selection.

5. The genetic marker section. This is value added but the subtitle "genetic markers" is a slightly underselling the value here. You are trying to map variants to genes to inform causal genes that are linking HDL-C size with CAD. It may worth stating this in the subtitle. Also, to make this section more informative, you can try a formal Wald ratio + colocalization analysis to estimate the putative causal effects of these HDL size related genes on CAD (rather than just did a SNP lookup in different GWASs).

6. Table 2, better to show 95%CI rather than just SE.

7. Discussion "small and medium HDL particles appear to be positively correlated with HDL cholesterol and ApoA1, their genetic correlations are much smaller than 1, indicating the existence of independent biological pathways." This statement is too strong by just using a statistical approach. Better to say "indicating possible independent biological pathway(s)."

https://doi.org/10.7554/eLife.58361.sa1

Author response

Essential revisions:

There are aspects of the study design that could be improved and discussed more critically because some of the interpretations are not straightforward. Overall comprehension of the paper would be greatly aided by a more detailed consideration of the relationship between the different lipoprotein classes and subclasses, and a clear explanation of parameters of interest.

Essential are a substantially clearer description of the results (requiring major revision of the manuscript), stronger justification of the statistical approach taken and explanation as to why results for some fractions are not presented. A preferred alternative is to present results for all fractions even if only in supplementary tables.

We would like to thank the referees and editors for carefully reviewing our manuscript and giving the constructive comments. We have implemented new analyses and substantially revised our manuscript. The main changes include:

1. We have made it clear in the Introduction that the goal of this study is to use genetic data to "discover lipoprotein subfractions that may be causal risk factors for CAD and MI in addition to the traditional lipid profile". To this end, we used the estimated genetic correlation with the traditional lipid traits to screen the subfraction measurements. This allows us to identify lipoprotein subfractions that may involve independent biological mechanisms before we look at the data about coronary artery disease.

2. We have redesigned our multivariable MR analyses, in which all the tradition lipid risk factors were included as exposures. Following the suggestion of a referee, we now considered two multivariable MR designs:

– In the first design, the exposures are TG, LDL-C, HDL-C, and the subfraction measurement under investigation;

– In the second design, the exposures are TG, ApoB, ApoA1, and the subfraction measurement under investigation.

The results of these two multivariable MR designs were largely comparable.

1. To make the results easier to interpret, we have moved the results of most of the univariable MR analyses to the Online Supplement. This also makes the Materials and methods in the main manuscript more straightforward.

2. We have revised the procedure of identifying genetic markers of interest. Because the main conclusion of our study is that HDL particle size may play a role in coronary artery disease, we selected SNPs that are associated with small or medium HDL subfractions and with CAD, but are not associated with LDL cholesterol or ApoB. Using this procedure, we identified four genetic markers for HDL size.

3. We have rewritten the Results section and the interpretation of the results in Discussion.

1. In the abstract and text please modify the use of the terms positive and negative effects. Clinicians interpret positive as meaning beneficial when referring to outcomes eg in RCTs and negative as ineffective or harmful. In this paper positive and negative appropriately refer to the directions of the associations found. To remove any potential ambiguity for readers please consider using positive (harmful) and negative (protective) or a similar rewording of your choice when these terms first appear in the abstract and main text.

Thank you. We have revised the usage of positive and negative effects in the manuscript.

2. The analyses presented are laudably thorough in detail, using different combinations of datasets in which variants to be used for analysis are identified in different summary statistics from those used for the MR itself. There does not appear to have been a prior hypothesis to this work. Rather, it seems that all possible analyses have been conducted and the results then mined for potentially noteworthy findings. While such analyses are useful in themselves the conclusions drawn are suspect and, in places, contradicted by other parts of the authors' own results. The main results also rest on a new method which has yet to be established as valid or workable in this context – GRAPPLE has only recently been described in a bioRXiV preprint, applied to traits with well over 100 independent genome-wide associations, and separate publication resting almost entirely on results using it, applied to traits with much less well-powered GWAS, is premature at best.

Thank you for the feedback. We had suspected that HDL particles may have a complicated and heterogeneous role prior to this work. For example, in a prior study (Zhao et al., Int J Epidemiol. 2019 Oct;48:1478-92), we concluded that "Further investigations are needed to demystify the observational and genetic associations between HDL-C and CAD." However, we did not want to restrict to this single hypothesis, because more information can be obtained and no real extra effort is needed by considering all lipid subfraction traits simultaneously. By being more agnostic, we also avoid the perils of selection/publication bias. This makes the current study slightly less powerful as we need to adjust for multiple testing, but we thought it is a price worth paying.

It is true that the GRAPPLE paper has not been published in a journal. On the other hand, we truly believe GRAPPLE has solved several issues in existing methods for multivariable MR and is more powerful. You are correct that the GWAS in this study are less well-powered, which is exactly the situation GRAPPLE is superior over other methods because it utilizes weak instruments efficiently and avoids weak instrument bias. So it would be a pity if we don’t use GRAPPLE here for this study. But we understand the concerns of relying the results on an unpublished methodological article and would understand if the editors want to put the publication of this manuscript on hold before the paper describing GRAPPLE finishes the peer-review process.

3. Genetic correlation analysis – The genetic correlation analysis seems to be stand alone to other MR analyses. The listed motivation of this analysis is to check whether the MR findings are independent to each other. However, it is clear that all these lipid sub-fractions are highly correlated to each other (genetically and observationally), especially for VLDL and LDL sub-fractions. So the rationale of linking TG with VLDL was not tested (although biologically VLDL is the main particle carrying TG in fasting). Even in a clustering point of view, it is hard to split the lipid sub-fraction into three groups: VLDL-TG, IDL/LDL-LDL-C and HDL-HDL-C.

Also some of the rg estimates are missing in Figure 1, e.g. TG is related to the key findings but not included in this genetic correlation analysis.

Also, in a method point of view there are some new genetic correlation methods coming out recently https://www.nature.com/articles/s41588-020-0653-y, which could be considered.

We have thought about the role of the genetic correlation analysis and redesigned our study. The estimated genetic correlations are now used to screen the lipid subfractions and remove those who are highly genetically correlated with the traditional lipid profile. Those subfractions are uninteresting because they do not seem to involve independent biological mechanisms and make the results of the multivariable MR analyses unstable.

We now included the genetic correlations with TG in the results. We found that all VLDL traits (besides a few related to very small VLDL) have extremely high (close to 1) genetic correlations with TG. In consequence, they were excluded from the MR analysis. We no longer group the lipid subfractions in the main manuscript, although the clustering was kept in some tables in the Online Supplement to make the results more organized.

Thanks for suggesting the new method for estimating genetic correlation via the high-definition likelihood. We tried it with a few traits and found the software is much slower than that of LD score regression. Because we needed to compute a very large number of genetic correlations and the precision of LD score regression seemed to be enough for our purposes, we did not switch to the high-definition likelihood approach in this study.

4. Instrument selection – From a practical point of view, It is tricky to jointly model TG with VLDL subtypes characteristics in MVMR because it is unlikely that one would have genetic instruments that strongly predict each exposure once adjusting for the others. Therefore, weak instrument bias is probably an issue here. This is worrying as weak instrument bias in MVMR is not necessarily conservative. At a minimum please provide the conditional F statistics for the MVMR model for each exposure.

Thank you for bringing up this valuable point. This is actually why we did not adjust for TG in multivariable MR analyses of VLDL subfractions in the original submission, but that seemed to have made the results more difficult to interpret. In the revision, most of the VLDL subfractions were excluded from the MR analysis due to their high genetic correlation with TG (see reply to point 3 above). We also decided to use the same set of traditional lipid risk factors in multivariable MR for different subfractions. So for VLDL subfractions, we adjusted for TG, LDL-C, and HDL-C (or TG, ApoB, and ApoA1). In Online Supplement C.4, we reported the conditional Cochran’s Q statistics for the multivariable MR models as described in the following article: Eleanor Sanderson, George Davey Smith, Frank Windmeijer, Jack Bowden, An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings, International Journal of Epidemiology, Volume 48, Issue 3, June 2019, Pages 713727, https://doi.org/10.1093/ije/dyy262.

5. The authors present a large amount of results for (unadjusted) univariate MR. Given the known highly pleiotropic nature of variants affecting lipoproteins and their sub-fractions, presentation of these in the main figure adds little and obscures the main results of potential note. The full results could be presented as supplementary data, but the main figures should be restricted to multivariable MR.

We have moved most of the univariable MR results to the Online Supplement. In Figure 2 of the main manuscript, we now report the results of one univariable MR analysis and two multivariable MR analyses.

6. Independent effects of lipid sub-fractions? multivariable MR (MVMR)

One of the key issue for lipids sub-fractions (and other metabolites such as fatty acids) is all the sub-fractions are highly correlated to each other. It is almost impossible to include all of the sub-fractions in the same MVMR model. Some methods considering reduce the dimensionality to solve this issue. In this study, the author used a different approach, which split the lipid sub-fractions into three classes, HDL, LDL and TG related. In this way, the MVMR could be conducted with limited number of variables. However, a lot of SNPs are associated with two or more lipid phenotypes, e.g. the CETP example the author provided in Table 3, the SNP is associated with HDL-C, LDL-C and TG. Even in a MVMR model controlling for LDL-C and TG, it is still hard to prove that the highlighted M-HDL-P finding showed an independent effect on CAD.

Also, more and more studies considered APOB and APOA1 in the MVMR model (e.g. https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1003062), so at least worth including APOB/APOA1 in the MVMR model.

Thank you for the suggestions. We have used genetic correlation analysis to pre-screen the lipid subfractions and reduce the dimensionality. Our purpose was not to identify the single "most causal" subfraction. Rather, we were generically interested in whether the lipid subfractions provide any additional value on top of the traditional risk factors. We hope this becomes clearer in the revision.

It is true that many SNPs are still associated with the lipid subfractions under investigation and some traditional lipid risk factors. We have implemented a new procedure to identify genetic markers for medium HDL and HDL size that are not associated with LDL-C or ApoB. In the Discussion, we made it clear that "the role of HDL particles in preventing CAD may be more complicated than, for example, that of LDL cholesterol or ApoB."

Thank you for the pointer to using ApoB and ApoA1 in MVMR. This is now included in our study as well. The results are generally not too different from using LDL-C and HDL-C, although ApoB does seem to have a slightly larger estimated effect than LDL-C and seems to "take away" some of the estimated effect of TG (see Table 2).

7. VLDL MR results – For VLDL results, some of them showed negative effects (CIs did not cross OR=1) in the MVMR model but positive effect in UVMR model, which seems complex and did not fit with the simple interpretation that "VLDL subfraction traits had uniformly positive effect on coronary artery disease" mentioned in the abstract. Can the authors discuss this in a bit more details and try to find the reason?

Thank you for pointing this out. The VLDL subfractions had very high genetic correlations with TG (and to some extent, with ApoB, see Supplement Table B2). So it is very unlikely that a genetic analysis can differentiate the VLDL subfractions from the traditional risk factors, if there is any. Due to this reason, we now exclude most of them from the MR analysis (see also the reply to point 3 above).

8. There are multiple lipidomics measures which are available from the NMR platform, but which are not analyzed, including critical ones such as M-HDL-TG. This needs explanation and/or rectification, since complete data would address multiple points. For instance, the authors dismiss the positive association of S-HDL-TG as being confounded by correlation with VLDL fractions, despite VLDL fractions not having any independent positive effect on CAD in the multivariable analysis. Results for M-HDL-TG would be very informative, and would avoid the possibility that erroneous conclusions are drawn simply because contrary data is missing.

In the genetic correlation analysis, it seems that S-HDL-TG is highly correlated with TG and behave more like a VLDL subfraction than an HDL subfraction (and thus is removed from the main MR analysis, see reply to point 3 above). The other triglyceride measurement for a HDL subfraction, XL-HDL-TG, had a much weaker genetic correlation with TG (see Table B2). We agree with you that an analysis for M-HDL-TG could be quite informative, but unfortunately data about M-HDL-TG were not reported in the two lipidomic GWAS available to us.

9. It is unclear that it is appropriate to adjust for overall LDL-C when analyzing HDL sub-fractions. Attempting to analyze sub-fractions of one class alongside an aggregate measure of another (which is correlated with aggregate measures of the first) seems suspect and at the very least requires detailed and careful justification.

Thank you for this interesting point. As explained in our reply to point 6, our purpose was not to identify the single "most causal" subfraction. Rather, we were generically interested in whether the lipid subfractions provide any additional value on top of the traditional risk factors. Relatedly, any subfraction discovered in the MR analysis is not necessarily the only causal agent. In the Discussion, we made it clear that "it is possible that HDL cholesterol, HDL subfractions, and HDL particle size are all phenotypic markers for some underlying causal mechanism." We then discussed possible connections with the HDL function hypothesis and the cholesterol efflux capacity.

10. The introduction anticipates the resolution of conflicting findings in relation to LDL size. This is dealt with in discussion, but it needs to be be highlighted beforehand in results. Since levels of different sized LDL and VLDL particles are strongly correlated, a statement that different sizes are not differently atherogenic is not supported by the data. To draw this conclusions would require multivariable MR in which the different size classes were adjusted for each other. In fact, the statement is directly contradicted by the clear associations of VLDL and (particularly) LDL diameter with CAD.

Thank you. We now made it clear in the Results section that "The mean diameter of LDL particles (LDL-D) showed a harmful effect on MI in univariable MR, though the effect was smaller than those of the LDL subfractions in univariable MR. The estimated effect of LDL-D was attenuated in the multivariable MR analyses." In the Discussion, we concluded that "we find some weak evidence that larger LDL particle size may have a small harmful effect on myocardial infarction and coronary artery disease." We were a little conservative in this conclusion because there was not a very convincing evidence from the multivariable MR analyses. The individual LDL subfractions had the right trend in multivariable MR (see Figure C4), but the confidence intervals were quite wide due to strong genetic correlation with LDL-C/ApoB. In one multivariable MR, LDL-D showed a protective effect, but it was barely statistically significant.

11. Similarly the statement that medium and small HDL particles are protective is contradicted by the fact that HDL particle diameter shows no association at all with CAD risk.

Thank you for this observation. HDL-D was not associated with CAD risk in univariable MR, but did show a positive effect in multivariable MR analyses now (notice that HDL-C/ApoA1 is now included in the multivariable MR for HDL-D, but was not included in the original submission). It turns out that adjusting for HDL-C/ApoA1 is quite important here, see Table 2. We do not interpret this as a necessary contradiction to the findings about small and medium HDL particles, but do acknowledge that the mechanism involving HDL particle size may be quite complicated. In the Discussion, we stated the following: "Notice that the harmful effect of larger HDL particle diameter found in this study relies on including HDL-C or ApoA1 in the multivariable MR analysis. Thus, the role of HDL particles in preventing CAD may be more complicated than, for example, that of LDL cholesterol or ApoB. It is possible that HDL cholesterol, HDL subfractions, and HDL particle size are all phenotypic markers for some underlying causal mechanism."

12. Selection of lipid sub-fractions – 82 lipid sub-fractions were selected but it is not directly clear why these fractions (but not others) were selected. It will be helpful to have a DAG to explain the inclusion and exclusion criteria. There is an even more fundamental question: Does this data justify a re-classification of NMR lipoprotein subclasses? Most people would agree that 82 is a few too many. Can the authors nominate a rational condensation of NMR lipoprotein sub-fraction data into a handful of independently predictive parameters with putative mechanisms? Ideally, these would be targets for therapy and indicators of response.

We did not select the lipid subfractions. The 82 subfractions were those reported in the lipidome GWAS that are related to VLDL, LDL, IDL, and HDL. This is now made clear in the beginning of Materials and methods.

Thank you for the suggestion about condensing the subfraction data. As described in the reply to point 3, we now use genetic correlation to screen the subfractions and remove the ones with highly genetic correlations with the traditional lipid risk factors (TG, LDL-C, HDL-C, ApoB, or ApoA1). This left us with 27 traits. Although one may argue that is still a few too many, we wanted to be more agnostic about generating hypotheses and let the data to speak for themselves. Relatedly, the purpose of this study was not to identify the single "most causal" subfraction. Rather, we were generically interested in whether the lipid subfractions provide any additional value on top of the traditional risk factors. In the Discussion, we pointed that the role of HDL particle size may be complicated and avoided making simple-minded conclusions like "increasing M-HDL-P by any means is causally protective, period".

13. HDL MR results – For S-HDL-TG, this is a very complex case and it is doubtful if the current setting can distinguish its effect driven by HDL from its effect driven by TG. I personally think its strong genetic correlation with VLDL (Figure 1) implies that the effect of S-HDL-TG on CAD is driven by TG. However, the MVMR adjusted TG showed similar effect estimate, which suggest the effect is independent to TG (as mentioned about, the reviewer is not sure the MVMR model can prove independent effect). The authors may need to consider integrating some biological information of each instruments been used here to dig into the button of this case study. For example, whether each of instrument colocalized with the expression level of the cis gene in multiple tissues. For the colocalized genes, are they related to HDL pathway or TG pathway etc. This could be very complex so the reviewer suggests to explain the results with caution.

For M-HDL-P, it showed some correlations with HDL-C and APOA1, so hard to say it is not correlated with HDL-C at all.

We agree that it is impossible to make any conclusions about S-HDL-TG because of its high genetic correlation with TG. In fact, S-HDL-TG has been excluded from the main MR analysis in our new design with phenotypic screening. It is true that M-HDL-P is genetically correlated with HDL-C and ApoA1, but adjusting for HDL-C and ApoA1 did not alter the estimated effect of M-HDL-P (the story is different for HDL-D). In summary, we think there is enough evidence to suggest that S-HDL-P and MHDL-P are risk factors that are reasonably independent of the traditional HDL-C and ApoA1. However, we also made it clear in the Discussion that the role of HDL particle size may be quite complicated.

Thank you for the suggestion about integrating biological information. We have used a new procedure to identify instruments associated with HDL particle sizes but not with LDL-C or ApoB. We have also included the cis genes that show up in eQTL data.

14. The identification of a leading role for mid-sized HDL particles presents a tantalizing opportunity to link the latter finding with recent NMR studies of cholesterol efflux, but this is not pursued. It would be worth flagging this opportunity at least in the discussion if you cannot easily address it. How do the results (M-HDL-P etc) relate to NMR assessments of cholesterol efflux capacity (eg Direct estimation of HDL-mediated cholesterol efflux capacity from serum). Sanna Kuusisto, Michael V. Holmes, Pauli Ohukainen, Antti J. Kangas, Mari Karsikas, Mika Tiainen, Markus Perola, Veikko Salomaa, Johannes Kettunen, Mika Ala-Korpela

doi: https://doi.org/10.1101/396929, now published in Clinical Chemistry doi: 10.1373/clinchem.2018.299222.

Thank you. We agree this is a tantalizing opportunity and a MR study for cholesterol efflux capacity can complement the results here. This is mentioned in the last paragraph of Discussion as a future work.

15. The multiple versions of the analysis using different combinations of datasets do provide worthwhile technical replication. However, these do not provide wider replication of the findings since any shortcomings in one analysis (e.g. in failing to fully address pleiotropy) will inevitably be present in another.

We agree with your assessment and have moved the results of the replication analyses to the Online Supplement.

16. A failure to find evidence against the INSIDE assumption, on the basis of only a small number of SNPs, is a very weak basis for making a claim that there is not horizontal pleiotropy affecting LDL-C or TG. The arguments made by the authors on this point are very weak.

We agree, although this is the best we could do to assess the InSIDE assumption. We have deemphasized this in the paper.

17. The issue of horizontal pleiotropy, especially as it applies to m-HDL-P in relation to the inSIDE assumptions for TG and LDL-C, is justified in discussion and acknowledged in limitations, but it is very difficult follow. For example, from table 3, TG is strongly associated with all traits apart from LOC157273, LIPG and DOCK6. Accordingly, the simple clinician is tempted to regard m-HDL-P as a surrogate for TG. Perhaps there needs to be greater clarity concerning the concepts of genetic correlation and "weak instrument bias".

Thank you for the suggestion. Although TG is strongly associated with several instruments for M-HDL-P, their associations were actually in different directions (see Table D9 in the Supplement) and are consistent with the InSIDE assumption. So M-HDL-P should not be regarded as a surrogate for TG. We have moved the diagnostics plots for M-HDL-P to the Online Supplement and only presented the genetic markers that are not associated with LDL-C or ApoB in the main paper. The four genetic markers we identified had no or weak associations with TG.

18. Discussion – "Our results for the HDL sub-fractions support the conclusion that HDL-C is not the causally relevant biomarker." The MR estimate of S-HDL-TG, M-HLD-C and M-HDL-L showed the complexity of HDL-C on CAD. So this claim seems against the main finding of the manuscript.

We meant HDL-C is not causal in the narrow sense that any intervention that increases HDLC will protect against CAD. Essentially we were trying to convey that the role of HDL is complicated, but we agree that this statement is not accurate. In the revised Discussion, we removed this sentence and made it clear that "Thus, the role of HDL particles in preventing CAD may be more complicated than, for example, that of LDL cholesterol or ApoB. It is possible that HDL cholesterol, HDL subfractions, and HDL particle size are all phenotypic markers for some underlying causal mechanism."

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

The manuscript has been improved but there are some remaining issues noted by the reviewers that need to be addressed, as outlined below:

You have made substantial efforts to restructure the manuscript (e.g. using genetic correlation as a filtering step in the new version), highlighted the key findings of HDL particle size on CAD as well as identified four potential causal genes linking HDL particle size with CAD. We are in general more convinced that the new findings from this study will bring good value for the existing argument for effect of HDL on CAD.

We appreciate the additional comments and suggestions by the reviewers. We have revised the manuscript accordingly.

The only suggested change we did not implement is the second part of issue 5:

Also, to make this section more informative, you can try a formal Wald ratio + colocalization analysis to estimate the putative causal effects of these HDL size related genes on CAD (rather than just did a SNP lookup in different GWASs).

This is an interesting suggestion, but we did not make the change because we think the Wald ratio estimator might not provide a full picture of the potential mechanisms involved. In particular, the genetic markers in Figure 3 are not only related to HDL particle size but also the overall HDL cholesterol. The last two markers also have a small association with triglycerides. We are worried that reporting the Wald ratio estimates may provide an oversimplified summary of the information in Figure 3 to the reader. That being said, we are also submitting the raw data for Figure 3. So if some reader is interested in knowing the putative causal effect, they can also take a ratio easily themselves.

https://doi.org/10.7554/eLife.58361.sa2

Article and author information

Author details

  1. Qingyuan Zhao

    Statistical Laboratory, University of Cambridge, Cambridge, United Kingdom
    Contribution
    Conceptualization, Data curation, Software, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Project administration
    For correspondence
    qyzhao@statslab.cam.ac.uk
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9902-2768
  2. Jingshu Wang

    Department of Statistics, University of Chicago, Chicago, United States
    Contribution
    Conceptualization, Data curation, Software, Validation, Investigation, Methodology, Writing - review and editing
    Competing interests
    No competing interests declared
  3. Zhen Miao

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Contribution
    Conceptualization, Investigation, Visualization, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3255-9517
  4. Nancy R Zhang

    Department of Statistics, University of Pennsylvania, Philadelphia, United States
    Contribution
    Conceptualization, Supervision, Visualization, Methodology, Writing - review and editing
    Competing interests
    No competing interests declared
  5. Sean Hennessy

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Contribution
    Resources, Supervision, Methodology, Writing - review and editing
    Competing interests
    No competing interests declared
  6. Dylan S Small

    Department of Statistics, University of Pennsylvania, Philadelphia, United States
    Contribution
    Conceptualization, Supervision, Investigation, Methodology, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4928-2646
  7. Daniel J Rader

    1. Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    2. Department of Medicine, University of Pennsylvania, Philadelphia, United States
    Contribution
    Conceptualization, Validation, Investigation, Writing - review and editing
    Competing interests
    No competing interests declared

Funding

No external funding was received for this work.

Senior Editor

  1. Matthias Barton, University of Zurich, Switzerland

Reviewing Editor

  1. Edward D Janus, University of Melbourne, Australia

Reviewers

  1. David Sullivan
  2. Jie Zheng, University of Bristol, United Kingdom

Version history

  1. Received: April 28, 2020
  2. Accepted: April 23, 2021
  3. Accepted Manuscript published: April 26, 2021 (version 1)
  4. Version of Record published: May 28, 2021 (version 2)

Copyright

© 2021, Zhao et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,938
    Page views
  • 226
    Downloads
  • 18
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Qingyuan Zhao
  2. Jingshu Wang
  3. Zhen Miao
  4. Nancy R Zhang
  5. Sean Hennessy
  6. Dylan S Small
  7. Daniel J Rader
(2021)
A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease
eLife 10:e58361.
https://doi.org/10.7554/eLife.58361

Further reading

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    William Matlock, Samuel Lipworth ... REHAB Consortium
    Research Article Updated

    Plasmids enable the dissemination of antimicrobial resistance (AMR) in common Enterobacterales pathogens, representing a major public health challenge. However, the extent of plasmid sharing and evolution between Enterobacterales causing human infections and other niches remains unclear, including the emergence of resistance plasmids. Dense, unselected sampling is essential to developing our understanding of plasmid epidemiology and designing appropriate interventions to limit the emergence and dissemination of plasmid-associated AMR. We established a geographically and temporally restricted collection of human bloodstream infection (BSI)-associated, livestock-associated (cattle, pig, poultry, and sheep faeces, farm soils) and wastewater treatment work (WwTW)-associated (influent, effluent, waterways upstream/downstream of effluent outlets) Enterobacterales. Isolates were collected between 2008 and 2020 from sites <60 km apart in Oxfordshire, UK. Pangenome analysis of plasmid clusters revealed shared ‘backbones’, with phylogenies suggesting an intertwined ecology where well-conserved plasmid backbones carry diverse accessory functions, including AMR genes. Many plasmid ‘backbones’ were seen across species and niches, raising the possibility that plasmid movement between these followed by rapid accessory gene change could be relatively common. Overall, the signature of identical plasmid sharing is likely to be a highly transient one, implying that plasmid movement might be occurring at greater rates than previously estimated, raising a challenge for future genomic One Health studies.

    1. Evolutionary Biology
    2. Genetics and Genomics
    Carolina A Martinez-Gutierrez, Josef C Uyeda, Frank O Aylward
    Research Article

    Microbial plankton play a central role in marine biogeochemical cycles, but the timing in which abundant lineages diversified into ocean environments remains unclear. Here, we reconstructed the timeline in which major clades of bacteria and archaea colonized the ocean using a high-resolution benchmarked phylogenetic tree that allows for simultaneous and direct comparison of the ages of multiple divergent lineages. Our findings show that the diversification of the most prevalent marine clades spans throughout a period of 2.2 Ga, with most clades colonizing the ocean during the last 800 million years. The oldest clades – SAR202, SAR324, Ca. Marinimicrobia, and Marine Group II – diversified around the time of the Great Oxidation Event, during which oxygen concentration increased but remained at microaerophilic levels throughout the Mid-Proterozoic, consistent with the prevalence of some clades within these groups in oxygen minimum zones today. We found the diversification of the prevalent heterotrophic marine clades SAR11, SAR116, SAR92, SAR86, and Roseobacter as well as the Marine Group I to occur near to the Neoproterozoic Oxygenation Event (0.8–0.4 Ga). The diversification of these clades is concomitant with an overall increase of oxygen and nutrients in the ocean at this time, as well as the diversification of eukaryotic algae, consistent with the previous hypothesis that the diversification of heterotrophic bacteria is linked to the emergence of large eukaryotic phytoplankton. The youngest clades correspond to the widespread phototrophic clades Prochlorococcus, Synechococcus, and Crocosphaera, whose diversification happened after the Phanerozoic Oxidation Event (0.45–0.4 Ga), in which oxygen concentrations had already reached their modern levels in the atmosphere and the ocean. Our work clarifies the timing at which abundant lineages of bacteria and archaea colonized the ocean, thereby providing key insights into the evolutionary history of lineages that comprise the majority of prokaryotic biomass in the modern ocean.